CN1143364A - 5-ht3受体激动剂、新颖的噻唑衍生物及其中间体 - Google Patents
5-ht3受体激动剂、新颖的噻唑衍生物及其中间体 Download PDFInfo
- Publication number
- CN1143364A CN1143364A CN95192012A CN95192012A CN1143364A CN 1143364 A CN1143364 A CN 1143364A CN 95192012 A CN95192012 A CN 95192012A CN 95192012 A CN95192012 A CN 95192012A CN 1143364 A CN1143364 A CN 1143364A
- Authority
- CN
- China
- Prior art keywords
- ring
- compound
- group
- methyl
- indeno
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007979 thiazole derivatives Chemical class 0.000 title claims abstract description 12
- 102000035037 5-HT3 receptors Human genes 0.000 title abstract 2
- 108091005477 5-HT3 receptors Proteins 0.000 title abstract 2
- 239000000018 receptor agonist Substances 0.000 title description 6
- 229940044601 receptor agonist Drugs 0.000 title description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 18
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims abstract description 12
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 11
- -1 Sauerstoffatom Chemical group 0.000 claims description 175
- 150000001875 compounds Chemical class 0.000 claims description 147
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 72
- 150000003839 salts Chemical class 0.000 claims description 35
- 125000000217 alkyl group Chemical group 0.000 claims description 33
- 125000006239 protecting group Chemical group 0.000 claims description 30
- 125000001118 alkylidene group Chemical group 0.000 claims description 27
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 24
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical group CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims description 24
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 24
- CYEBJEDOHLIWNP-UHFFFAOYSA-N methanethioamide Chemical compound NC=S CYEBJEDOHLIWNP-UHFFFAOYSA-N 0.000 claims description 22
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 22
- 125000004429 atom Chemical group 0.000 claims description 20
- 150000001412 amines Chemical group 0.000 claims description 17
- 150000001721 carbon Chemical group 0.000 claims description 16
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 15
- 125000004432 carbon atom Chemical group C* 0.000 claims description 14
- 125000005843 halogen group Chemical group 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 13
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical group CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 9
- 125000002619 bicyclic group Chemical group 0.000 claims description 8
- 125000002252 acyl group Chemical group 0.000 claims description 7
- 125000004043 oxo group Chemical group O=* 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- 230000002496 gastric effect Effects 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- DLZRWAPCAZDVMQ-UHFFFAOYSA-N 2-pyrrolidin-3-yl-4h-indeno[1,2-d][1,3]thiazole Chemical compound C1NCCC1C(S1)=NC2=C1CC1=CC=CC=C21 DLZRWAPCAZDVMQ-UHFFFAOYSA-N 0.000 claims description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 3
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 3
- YUKQRDCYNOVPGJ-UHFFFAOYSA-N thioacetamide Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 claims description 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000002573 ethenylidene group Chemical group [*]=C=C([H])[H] 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 221
- 238000001819 mass spectrum Methods 0.000 description 131
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 121
- 239000007858 starting material Substances 0.000 description 107
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 73
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 69
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 65
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 62
- 238000004458 analytical method Methods 0.000 description 59
- 239000002904 solvent Substances 0.000 description 52
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 48
- 239000000243 solution Substances 0.000 description 48
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 45
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 40
- 238000000034 method Methods 0.000 description 35
- 235000002639 sodium chloride Nutrition 0.000 description 34
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 33
- 238000006243 chemical reaction Methods 0.000 description 31
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- 238000002425 crystallisation Methods 0.000 description 22
- 230000008025 crystallization Effects 0.000 description 22
- 238000001035 drying Methods 0.000 description 21
- 230000000694 effects Effects 0.000 description 21
- 238000010992 reflux Methods 0.000 description 20
- 238000000605 extraction Methods 0.000 description 19
- 239000000203 mixture Substances 0.000 description 19
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 18
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 15
- 239000001530 fumaric acid Substances 0.000 description 14
- 239000010410 layer Substances 0.000 description 14
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 239000000460 chlorine Substances 0.000 description 12
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 12
- 238000000354 decomposition reaction Methods 0.000 description 12
- 238000002386 leaching Methods 0.000 description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 12
- 239000003960 organic solvent Substances 0.000 description 12
- 238000001953 recrystallisation Methods 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 11
- 239000003513 alkali Substances 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000000543 intermediate Substances 0.000 description 10
- 238000006722 reduction reaction Methods 0.000 description 10
- 238000010898 silica gel chromatography Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 239000001301 oxygen Substances 0.000 description 9
- 239000002994 raw material Substances 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 8
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 8
- 235000011114 ammonium hydroxide Nutrition 0.000 description 8
- 230000008602 contraction Effects 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 239000000556 agonist Substances 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 239000000470 constituent Substances 0.000 description 7
- 238000004090 dissolution Methods 0.000 description 7
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 7
- 150000002825 nitriles Chemical class 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- WSWWYTGGNKIPSK-UHFFFAOYSA-N 4h-indeno[1,2-d][1,3]thiazole Chemical compound C1C2=CC=CC=C2C2=C1SC=N2 WSWWYTGGNKIPSK-UHFFFAOYSA-N 0.000 description 6
- 241000700199 Cavia porcellus Species 0.000 description 6
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- IANQTJSKSUMEQM-UHFFFAOYSA-N benzofuran Natural products C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 6
- 210000001072 colon Anatomy 0.000 description 6
- 230000008030 elimination Effects 0.000 description 6
- 238000003379 elimination reaction Methods 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- XUOQPOYHVDZLPR-UHFFFAOYSA-N propanethioamide;hydrochloride Chemical compound Cl.CCC(N)=S XUOQPOYHVDZLPR-UHFFFAOYSA-N 0.000 description 6
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 6
- OSANFONRYANBRD-WLHGVMLRSA-N (e)-but-2-enedioic acid;octane Chemical compound CCCCCCCC.OC(=O)\C=C\C(O)=O OSANFONRYANBRD-WLHGVMLRSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 150000003840 hydrochlorides Chemical class 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- JRHZGESMAJFUOR-UHFFFAOYSA-N 2-(pyrrolidin-3-ylmethyl)-4h-indeno[1,2-d][1,3]thiazole Chemical compound N=1C(C2=CC=CC=C2C2)=C2SC=1CC1CCNC1 JRHZGESMAJFUOR-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 238000000862 absorption spectrum Methods 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 239000003701 inert diluent Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 235000012204 lemonade/lime carbonate Nutrition 0.000 description 4
- ZCYXXKJEDCHMGH-UHFFFAOYSA-N nonane Chemical compound CCCC[CH]CCCC ZCYXXKJEDCHMGH-UHFFFAOYSA-N 0.000 description 4
- BKIMMITUMNQMOS-UHFFFAOYSA-N normal nonane Natural products CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 4
- 235000015320 potassium carbonate Nutrition 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 150000003335 secondary amines Chemical class 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 229930192474 thiophene Natural products 0.000 description 4
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 3
- XRXXSJSHNVNRAR-UHFFFAOYSA-N 2-(1-methylpyrrolidin-3-yl)-4h-indeno[1,2-d][1,3]thiazole Chemical compound C1N(C)CCC1C(S1)=NC2=C1CC1=CC=CC=C21 XRXXSJSHNVNRAR-UHFFFAOYSA-N 0.000 description 3
- VIYZGXAHGHTKFD-UHFFFAOYSA-N 2-(pyridin-3-ylmethyl)-4h-indeno[1,2-d][1,3]thiazole Chemical compound N=1C(C2=CC=CC=C2C2)=C2SC=1CC1=CC=CN=C1 VIYZGXAHGHTKFD-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- KXNQKOAQSGJCQU-UHFFFAOYSA-N benzo[e][1,3]benzothiazole Chemical compound C1=CC=C2C(N=CS3)=C3C=CC2=C1 KXNQKOAQSGJCQU-UHFFFAOYSA-N 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 150000001728 carbonyl compounds Chemical class 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000006837 decompression Effects 0.000 description 3
- 230000013872 defecation Effects 0.000 description 3
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 150000002240 furans Chemical class 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 150000003141 primary amines Chemical class 0.000 description 3
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 3
- 229960002073 sertraline Drugs 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 125000000542 sulfonic acid group Chemical group 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- LYDPYVLIZGQINV-UHFFFAOYSA-N 2-(1,3-dioxoisoindol-2-yl)ethanethioamide Chemical compound C1=CC=C2C(=O)N(CC(=S)N)C(=O)C2=C1 LYDPYVLIZGQINV-UHFFFAOYSA-N 0.000 description 2
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 2
- MMUPBTLQZNVHJQ-UHFFFAOYSA-N 2-(4h-indeno[1,2-d][1,3]thiazol-2-ylmethyl)isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1CC(S1)=NC2=C1CC1=CC=CC=C21 MMUPBTLQZNVHJQ-UHFFFAOYSA-N 0.000 description 2
- MUECYQPNEZIAQM-UHFFFAOYSA-N 2-[(1-benzylpiperidin-2-yl)methyl]-4-thiophen-2-yl-1,3-thiazole Chemical class N=1C(C=2SC=CC=2)=CSC=1CC1CCCCN1CC1=CC=CC=C1 MUECYQPNEZIAQM-UHFFFAOYSA-N 0.000 description 2
- WGGQROPZJIKAFM-UHFFFAOYSA-N 2-[(1-benzylpyrrolidin-2-yl)methyl]-4h-indeno[1,2-d][1,3]thiazole Chemical compound N=1C(C2=CC=CC=C2C2)=C2SC=1CC1CCCN1CC1=CC=CC=C1 WGGQROPZJIKAFM-UHFFFAOYSA-N 0.000 description 2
- KRKIWZPJQXKRCE-UHFFFAOYSA-N 2-[(1-benzylpyrrolidin-3-yl)methyl]-4h-indeno[1,2-d][1,3]thiazole Chemical compound N=1C(C2=CC=CC=C2C2)=C2SC=1CC(C1)CCN1CC1=CC=CC=C1 KRKIWZPJQXKRCE-UHFFFAOYSA-N 0.000 description 2
- JTQRJRZKTOCWTP-UHFFFAOYSA-N 2-[2-(1-benzylpiperidin-2-yl)ethyl]-4-thiophen-2-yl-1,3-thiazole Chemical class C1CCCN(CC=2C=CC=CC=2)C1CCC(SC=1)=NC=1C1=CC=CS1 JTQRJRZKTOCWTP-UHFFFAOYSA-N 0.000 description 2
- XHXFLMJGZWUEQQ-UHFFFAOYSA-N 2-[2-(4h-indeno[1,2-d][1,3]thiazol-2-yl)ethyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1CCC(S1)=NC2=C1CC1=CC=CC=C21 XHXFLMJGZWUEQQ-UHFFFAOYSA-N 0.000 description 2
- 125000003504 2-oxazolinyl group Chemical group O1C(=NCC1)* 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical group N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 2
- JXZVFXWALWJZSE-UHFFFAOYSA-N 3-ethyloctanenitrile Chemical compound CCCCCC(CC)CC#N JXZVFXWALWJZSE-UHFFFAOYSA-N 0.000 description 2
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- PJUGXHKLGVPTPJ-UHFFFAOYSA-N C1=CC=CC1.[S] Chemical compound C1=CC=CC1.[S] PJUGXHKLGVPTPJ-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 206010029333 Neurosis Diseases 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- MNZMECMQTYGSOI-UHFFFAOYSA-N acetic acid;hydron;bromide Chemical compound Br.CC(O)=O MNZMECMQTYGSOI-UHFFFAOYSA-N 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- 230000008484 agonism Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 230000009989 contractile response Effects 0.000 description 2
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- IRDLUHRVLVEUHA-UHFFFAOYSA-N diethyl dithiophosphate Chemical compound CCOP(S)(=S)OCC IRDLUHRVLVEUHA-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical compound OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- AFKOCCJDYMXAHV-UHFFFAOYSA-N ethyl 4-(4h-indeno[1,2-d][1,3]thiazol-2-ylmethyl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1CC(S1)=NC2=C1CC1=CC=CC=C21 AFKOCCJDYMXAHV-UHFFFAOYSA-N 0.000 description 2
- 238000003810 ethyl acetate extraction Methods 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical class CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 208000015238 neurotic disease Diseases 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- WPZSAUFQHYFIPG-UHFFFAOYSA-N propanethioamide Chemical compound CCC(N)=S WPZSAUFQHYFIPG-UHFFFAOYSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 238000005932 reductive alkylation reaction Methods 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- ZDAQIMMALLPIMZ-UHFFFAOYSA-N tert-butyl n-[2-(4h-indeno[1,2-d][1,3]thiazol-2-yl)cyclopentyl]carbamate Chemical compound CC(C)(C)OC(=O)NC1CCCC1C(S1)=NC2=C1CC1=CC=CC=C21 ZDAQIMMALLPIMZ-UHFFFAOYSA-N 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 2
- 150000003557 thiazoles Chemical class 0.000 description 2
- WHLUQAYNVOGZST-UHFFFAOYSA-N tifenamil Chemical group C=1C=CC=CC=1C(C(=O)SCCN(CC)CC)C1=CC=CC=C1 WHLUQAYNVOGZST-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- QQXLDOJGLXJCSE-KNVOCYPGSA-N tropinone Chemical compound C1C(=O)C[C@H]2CC[C@@H]1N2C QQXLDOJGLXJCSE-KNVOCYPGSA-N 0.000 description 2
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 125000006557 (C2-C5) alkylene group Chemical group 0.000 description 1
- ZXKXJHAOUFHNAS-FVGYRXGTSA-N (S)-fenfluramine hydrochloride Chemical compound [Cl-].CC[NH2+][C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 ZXKXJHAOUFHNAS-FVGYRXGTSA-N 0.000 description 1
- FRBXHUUHIIGYDT-TYYBGVCCSA-N (e)-but-2-enedioic acid;1,3-thiazole Chemical compound C1=CSC=N1.OC(=O)\C=C\C(O)=O FRBXHUUHIIGYDT-TYYBGVCCSA-N 0.000 description 1
- QYXUHXHUNSTTCC-WLHGVMLRSA-N (e)-but-2-enedioic acid;1-[2-(4h-indeno[1,2-d][1,3]thiazol-2-yl)ethyl]-n,n-dimethylcyclohexan-1-amine Chemical compound OC(=O)\C=C\C(O)=O.N=1C(C2=CC=CC=C2C2)=C2SC=1CCC1(N(C)C)CCCCC1 QYXUHXHUNSTTCC-WLHGVMLRSA-N 0.000 description 1
- KVODJWMOSODNST-WLHGVMLRSA-N (e)-but-2-enedioic acid;2-(1-methylpiperidin-4-yl)-4h-indeno[1,2-d][1,3]thiazole Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C)CCC1C(S1)=NC2=C1CC1=CC=CC=C21 KVODJWMOSODNST-WLHGVMLRSA-N 0.000 description 1
- QGIBGLOCOVFDPV-WLHGVMLRSA-N (e)-but-2-enedioic acid;2-(1-methylpyrrolidin-3-yl)-4-(3-methylthiophen-2-yl)-1,3-thiazole Chemical compound OC(=O)\C=C\C(O)=O.C1N(C)CCC1C1=NC(C2=C(C=CS2)C)=CS1 QGIBGLOCOVFDPV-WLHGVMLRSA-N 0.000 description 1
- VEVYABBVNVZTAU-WLHGVMLRSA-N (e)-but-2-enedioic acid;2-(4h-indeno[1,2-d][1,3]thiazol-2-yl)-n,n-dimethylethanamine Chemical compound OC(=O)\C=C\C(O)=O.C1=CC=C2C(N=C(S3)CCN(C)C)=C3CC2=C1 VEVYABBVNVZTAU-WLHGVMLRSA-N 0.000 description 1
- LJNCHLJFHNNUMR-WLHGVMLRSA-N (e)-but-2-enedioic acid;2-(4h-indeno[1,2-d][1,3]thiazol-2-yl)ethanamine Chemical compound OC(=O)\C=C\C(O)=O.C1=CC=C2C(N=C(S3)CCN)=C3CC2=C1 LJNCHLJFHNNUMR-WLHGVMLRSA-N 0.000 description 1
- OWIZCXCTRVYYJS-WLHGVMLRSA-N (e)-but-2-enedioic acid;2-(pyrrolidin-2-ylmethyl)-4h-indeno[1,2-d][1,3]thiazole Chemical compound OC(=O)\C=C\C(O)=O.N=1C(C2=CC=CC=C2C2)=C2SC=1CC1CCCN1 OWIZCXCTRVYYJS-WLHGVMLRSA-N 0.000 description 1
- MMOJEFFIYDJLQS-WLHGVMLRSA-N (e)-but-2-enedioic acid;2-(pyrrolidin-3-ylmethyl)-4h-indeno[1,2-d][1,3]thiazole Chemical compound OC(=O)\C=C\C(O)=O.N=1C(C2=CC=CC=C2C2)=C2SC=1CC1CCNC1 MMOJEFFIYDJLQS-WLHGVMLRSA-N 0.000 description 1
- VHVYEUKNAFHZGT-WLHGVMLRSA-N (e)-but-2-enedioic acid;2-[(1-methylpiperidin-3-yl)methyl]-4h-indeno[1,2-d][1,3]thiazole Chemical compound OC(=O)\C=C\C(O)=O.C1N(C)CCCC1CC(S1)=NC2=C1CC1=CC=CC=C21 VHVYEUKNAFHZGT-WLHGVMLRSA-N 0.000 description 1
- ZZNTUCPQXIXJMU-WLHGVMLRSA-N (e)-but-2-enedioic acid;2-[(1-methylpyrrolidin-2-yl)methyl]-4h-indeno[1,2-d][1,3]thiazole Chemical compound OC(=O)\C=C\C(O)=O.CN1CCCC1CC(S1)=NC2=C1CC1=CC=CC=C21 ZZNTUCPQXIXJMU-WLHGVMLRSA-N 0.000 description 1
- KMJOQRVVFAEOBR-WLHGVMLRSA-N (e)-but-2-enedioic acid;2-[(1-methylpyrrolidin-3-yl)methyl]-4h-indeno[1,2-d][1,3]thiazole Chemical compound OC(=O)\C=C\C(O)=O.C1N(C)CCC1CC(S1)=NC2=C1CC1=CC=CC=C21 KMJOQRVVFAEOBR-WLHGVMLRSA-N 0.000 description 1
- LDMFIKYAJWTRHK-DKMXUPDOSA-N (e)-but-2-enedioic acid;2-[(3r)-pyrrolidin-3-yl]-4h-indeno[1,2-d][1,3]thiazole Chemical compound OC(=O)\C=C\C(O)=O.C1NCC[C@H]1C(S1)=NC2=C1CC1=CC=CC=C21 LDMFIKYAJWTRHK-DKMXUPDOSA-N 0.000 description 1
- LDMFIKYAJWTRHK-PBBCPHEYSA-N (e)-but-2-enedioic acid;2-[(3s)-pyrrolidin-3-yl]-4h-indeno[1,2-d][1,3]thiazole Chemical compound OC(=O)\C=C\C(O)=O.C1NCC[C@@H]1C(S1)=NC2=C1CC1=CC=CC=C21 LDMFIKYAJWTRHK-PBBCPHEYSA-N 0.000 description 1
- UEOUGRHRCCEZOZ-WLHGVMLRSA-N (e)-but-2-enedioic acid;2-[2-(1-methylpyrrolidin-2-yl)ethyl]-4h-indeno[1,2-d][1,3]thiazole Chemical compound OC(=O)\C=C\C(O)=O.CN1CCCC1CCC(S1)=NC2=C1CC1=CC=CC=C21 UEOUGRHRCCEZOZ-WLHGVMLRSA-N 0.000 description 1
- XKFDGYWPKQOBDQ-WLHGVMLRSA-N (e)-but-2-enedioic acid;3-(4h-indeno[1,2-d][1,3]thiazol-2-yl)propan-1-amine Chemical compound OC(=O)\C=C\C(O)=O.C1=CC=C2C(N=C(S3)CCCN)=C3CC2=C1 XKFDGYWPKQOBDQ-WLHGVMLRSA-N 0.000 description 1
- PAMVQEBQWPBYOB-WLHGVMLRSA-N (e)-but-2-enedioic acid;4-phenyl-2-piperidin-3-yl-1,3-thiazole Chemical compound OC(=O)\C=C\C(O)=O.C1CCNCC1C1=NC(C=2C=CC=CC=2)=CS1 PAMVQEBQWPBYOB-WLHGVMLRSA-N 0.000 description 1
- JSZIERUELMKQRO-WLHGVMLRSA-N (e)-but-2-enedioic acid;heptane Chemical compound CCCCCCC.OC(=O)\C=C\C(O)=O JSZIERUELMKQRO-WLHGVMLRSA-N 0.000 description 1
- ZLZISLYKANBVNC-WLHGVMLRSA-N (e)-but-2-enedioic acid;nonane Chemical compound OC(=O)\C=C\C(O)=O.CCCCCCCCC ZLZISLYKANBVNC-WLHGVMLRSA-N 0.000 description 1
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 1
- MDEXMBGPIZUUBI-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroquinoxaline Chemical group N1CCNC2CCCCC21 MDEXMBGPIZUUBI-UHFFFAOYSA-N 0.000 description 1
- LRGZZEOWQURWFK-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7-octahydroisoquinoline Chemical compound C1NCCC2CCCC=C21 LRGZZEOWQURWFK-UHFFFAOYSA-N 0.000 description 1
- CVPINKZPXNOVFO-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7-octahydroquinazoline Chemical group N1CNCC2CCCC=C21 CVPINKZPXNOVFO-UHFFFAOYSA-N 0.000 description 1
- CEKSPMMCISUSTR-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7-octahydroquinoline Chemical group C1CCC2CCCNC2=C1 CEKSPMMCISUSTR-UHFFFAOYSA-N 0.000 description 1
- FIDRAVVQGKNYQK-UHFFFAOYSA-N 1,2,3,4-tetrahydrotriazine Chemical group C1NNNC=C1 FIDRAVVQGKNYQK-UHFFFAOYSA-N 0.000 description 1
- OYWRDHBGMCXGFY-UHFFFAOYSA-N 1,2,3-triazinane Chemical group C1CNNNC1 OYWRDHBGMCXGFY-UHFFFAOYSA-N 0.000 description 1
- PPSPFVPYTWTEEP-UHFFFAOYSA-N 1,3-benzothiazole;oxalic acid Chemical compound OC(=O)C(O)=O.C1=CC=C2SC=NC2=C1 PPSPFVPYTWTEEP-UHFFFAOYSA-N 0.000 description 1
- AKQIJUCZWUAMNJ-UHFFFAOYSA-N 1,3-benzoxazole;quinoline Chemical compound C1=CC=C2OC=NC2=C1.N1=CC=CC2=CC=CC=C21 AKQIJUCZWUAMNJ-UHFFFAOYSA-N 0.000 description 1
- ABADUMLIAZCWJD-UHFFFAOYSA-N 1,3-dioxole Chemical compound C1OC=CO1 ABADUMLIAZCWJD-UHFFFAOYSA-N 0.000 description 1
- 125000000164 1,3-thiazinyl group Chemical group S1C(N=CC=C1)* 0.000 description 1
- CPRVXMQHLPTWLY-UHFFFAOYSA-N 1,4-oxathiine Chemical compound O1C=CSC=C1 CPRVXMQHLPTWLY-UHFFFAOYSA-N 0.000 description 1
- 125000000183 1,4-thiazinyl group Chemical group S1C(C=NC=C1)* 0.000 description 1
- HCWIEEVPMWVTRN-UHFFFAOYSA-N 1-(benzo[e][1,3]benzothiazol-2-ylmethyl)pyrrolidin-3-amine Chemical compound C1C(N)CCN1CC(S1)=NC2=C1C=CC1=CC=CC=C21 HCWIEEVPMWVTRN-UHFFFAOYSA-N 0.000 description 1
- AEONXKCZELMJMZ-UHFFFAOYSA-N 1-[2-(4h-indeno[1,2-d][1,3]thiazol-2-yl)ethyl]cyclohexan-1-amine Chemical compound N=1C(C2=CC=CC=C2C2)=C2SC=1CCC1(N)CCCCC1 AEONXKCZELMJMZ-UHFFFAOYSA-N 0.000 description 1
- DBAFFPICNKYNAC-UHFFFAOYSA-N 1-benzyl-2-(2-chloroethyl)piperidine Chemical compound ClCCC1CCCCN1CC1=CC=CC=C1 DBAFFPICNKYNAC-UHFFFAOYSA-N 0.000 description 1
- CPGUAMMBRXPVGH-UHFFFAOYSA-N 1-benzyl-2-(chloromethyl)piperidine Chemical compound ClCC1CCCCN1CC1=CC=CC=C1 CPGUAMMBRXPVGH-UHFFFAOYSA-N 0.000 description 1
- QSSXJPIWXQTSIX-UHFFFAOYSA-N 1-bromo-2-methylbenzene Chemical compound CC1=CC=CC=C1Br QSSXJPIWXQTSIX-UHFFFAOYSA-N 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- BJKKPDLNTVOVON-UHFFFAOYSA-N 1-methyl-5-oxopyrrolidine-3-carbonitrile Chemical compound CN1CC(C#N)CC1=O BJKKPDLNTVOVON-UHFFFAOYSA-N 0.000 description 1
- PDELQDSYLBLPQO-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-indole Chemical group C1CCCC2NCCC21 PDELQDSYLBLPQO-UHFFFAOYSA-N 0.000 description 1
- ODSNARDHJFFSRH-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-isoindole Chemical group C1CCCC2CNCC21 ODSNARDHJFFSRH-UHFFFAOYSA-N 0.000 description 1
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 1
- CDULGHZNHURECF-UHFFFAOYSA-N 2,3-dimethylaniline 2,4-dimethylaniline 2,5-dimethylaniline 2,6-dimethylaniline 3,4-dimethylaniline 3,5-dimethylaniline Chemical group CC1=CC=C(N)C(C)=C1.CC1=CC=C(C)C(N)=C1.CC1=CC(C)=CC(N)=C1.CC1=CC=C(N)C=C1C.CC1=CC=CC(N)=C1C.CC1=CC=CC(C)=C1N CDULGHZNHURECF-UHFFFAOYSA-N 0.000 description 1
- UPUWMQZUXFAUCJ-UHFFFAOYSA-N 2,5-dihydro-1,2-thiazole Chemical class C1SNC=C1 UPUWMQZUXFAUCJ-UHFFFAOYSA-N 0.000 description 1
- KJTIDLYAIIARFO-UHFFFAOYSA-N 2-(1,3-dioxoisoindol-2-yl)acetonitrile Chemical compound C1=CC=C2C(=O)N(CC#N)C(=O)C2=C1 KJTIDLYAIIARFO-UHFFFAOYSA-N 0.000 description 1
- FJAKBQXCFMUHQO-UHFFFAOYSA-N 2-(1-benzylpyrrolidin-3-yl)-4h-indeno[1,2-d][1,3]thiazole;hydrochloride Chemical compound Cl.C1CC(C=2SC3=C(C4=CC=CC=C4C3)N=2)CN1CC1=CC=CC=C1 FJAKBQXCFMUHQO-UHFFFAOYSA-N 0.000 description 1
- GSUCWCAJSXEYMP-UHFFFAOYSA-N 2-(1-methylpyrrolidin-3-yl)-4,5-dihydrobenzo[e][1,3]benzothiazole;dihydrochloride Chemical compound Cl.Cl.C1N(C)CCC1C(S1)=NC2=C1CCC1=CC=CC=C21 GSUCWCAJSXEYMP-UHFFFAOYSA-N 0.000 description 1
- ONVDSSZELXIOHS-UHFFFAOYSA-N 2-(1-methylpyrrolidin-3-yl)-4-(1,3-thiazol-2-yl)-1,3-thiazole;oxalic acid Chemical compound OC(=O)C(O)=O.C1N(C)CCC1C1=NC(C=2SC=CN=2)=CS1 ONVDSSZELXIOHS-UHFFFAOYSA-N 0.000 description 1
- CEHARPSWZVWJCX-UHFFFAOYSA-N 2-(1-methylpyrrolidin-3-yl)-4-thiophen-2-yl-1,3-thiazole;oxalic acid Chemical compound OC(=O)C(O)=O.C1N(C)CCC1C1=NC(C=2SC=CC=2)=CS1 CEHARPSWZVWJCX-UHFFFAOYSA-N 0.000 description 1
- WQZHGIDSHOPIBA-UHFFFAOYSA-N 2-(1-methylpyrrolidin-3-yl)-4-thiophen-3-yl-1,3-thiazole;oxalic acid Chemical compound OC(=O)C(O)=O.C1N(C)CCC1C1=NC(C2=CSC=C2)=CS1 WQZHGIDSHOPIBA-UHFFFAOYSA-N 0.000 description 1
- 125000003163 2-(2-naphthyl)ethyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(C([H])=C([H])C2=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- FSICBYKMTYEHFH-UHFFFAOYSA-N 2-(2-piperidin-2-ylethyl)-4-thiophen-2-yl-1,3-thiazole Chemical class C1CCCNC1CCC(SC=1)=NC=1C1=CC=CS1 FSICBYKMTYEHFH-UHFFFAOYSA-N 0.000 description 1
- GYHTWKLDJNQEHH-UHFFFAOYSA-N 2-(4H-indeno[1,2-d][1,3]thiazol-2-yl)cyclopentan-1-amine Chemical compound NC1CCCC1C(S1)=NC2=C1CC1=CC=CC=C21 GYHTWKLDJNQEHH-UHFFFAOYSA-N 0.000 description 1
- AYXCGRVCJXZJLH-UHFFFAOYSA-N 2-(4h-indeno[1,2-d][1,3]thiazol-2-yl)cyclohexan-1-amine Chemical compound NC1CCCCC1C(S1)=NC2=C1CC1=CC=CC=C21 AYXCGRVCJXZJLH-UHFFFAOYSA-N 0.000 description 1
- RIMRPQQSAODVRO-UHFFFAOYSA-N 2-(piperidin-2-ylmethyl)-4-thiophen-2-yl-1,3-thiazole Chemical class N=1C(C=2SC=CC=2)=CSC=1CC1CCCCN1 RIMRPQQSAODVRO-UHFFFAOYSA-N 0.000 description 1
- IZUILSRYWBLOOB-UHFFFAOYSA-N 2-(pyridin-4-ylmethyl)-4h-indeno[1,2-d][1,3]thiazole Chemical compound N=1C(C2=CC=CC=C2C2)=C2SC=1CC1=CC=NC=C1 IZUILSRYWBLOOB-UHFFFAOYSA-N 0.000 description 1
- VCSVRQRDFBCXOO-UHFFFAOYSA-N 2-(pyrrolidin-2-ylmethyl)-4h-indeno[1,2-d][1,3]thiazole Chemical compound N=1C(C2=CC=CC=C2C2)=C2SC=1CC1CCCN1 VCSVRQRDFBCXOO-UHFFFAOYSA-N 0.000 description 1
- VOLLRARLHMANMU-UHFFFAOYSA-N 2-[(1-benzylpiperidin-3-yl)methyl]-4h-indeno[1,2-d][1,3]thiazole;hydrate;dihydrochloride Chemical compound O.Cl.Cl.N=1C(C2=CC=CC=C2C2)=C2SC=1CC(C1)CCCN1CC1=CC=CC=C1 VOLLRARLHMANMU-UHFFFAOYSA-N 0.000 description 1
- LXKWXWLJFGXMKC-UHFFFAOYSA-N 2-[(1-benzylpyrrolidin-3-yl)methyl]-4h-indeno[1,2-d][1,3]thiazole;dihydrate;dihydrochloride Chemical compound O.O.Cl.Cl.N=1C(C2=CC=CC=C2C2)=C2SC=1CC(C1)CCN1CC1=CC=CC=C1 LXKWXWLJFGXMKC-UHFFFAOYSA-N 0.000 description 1
- DURBSGDVQLBIQK-UHFFFAOYSA-N 2-[(1-methylpyrrolidin-3-yl)methyl]-4H-indeno[1,2-d][1,3]thiazole Chemical compound C1N(C)CCC1CC(S1)=NC2=C1CC1=CC=CC=C21 DURBSGDVQLBIQK-UHFFFAOYSA-N 0.000 description 1
- DLZRWAPCAZDVMQ-JTQLQIEISA-N 2-[(3s)-pyrrolidin-3-yl]-4h-indeno[1,2-d][1,3]thiazole Chemical compound C1NCC[C@@H]1C(S1)=NC2=C1CC1=CC=CC=C21 DLZRWAPCAZDVMQ-JTQLQIEISA-N 0.000 description 1
- HELVTYGLGQPISJ-UHFFFAOYSA-N 2-[4-(4h-indeno[1,2-d][1,3]thiazol-2-yl)butyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1CCCCC(S1)=NC2=C1CC1=CC=CC=C21 HELVTYGLGQPISJ-UHFFFAOYSA-N 0.000 description 1
- GGRLKHMFMUXIOG-UHFFFAOYSA-M 2-acetyloxyethyl(trimethyl)azanium;hydroxide Chemical compound [OH-].CC(=O)OCC[N+](C)(C)C GGRLKHMFMUXIOG-UHFFFAOYSA-M 0.000 description 1
- AYNCWMIFKFADCZ-UHFFFAOYSA-N 2-bromo-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1=CC=C2C(=O)C(Br)CCC2=C1 AYNCWMIFKFADCZ-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- 125000003890 2-phenylbutyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- PTHDBHDZSMGHKF-UHFFFAOYSA-N 2-piperidin-2-ylethanol Chemical class OCCC1CCCCN1 PTHDBHDZSMGHKF-UHFFFAOYSA-N 0.000 description 1
- JUWPLISTCFAVAZ-UHFFFAOYSA-N 2-piperidin-4-ylbutanenitrile Chemical compound CCC(C#N)C1CCNCC1 JUWPLISTCFAVAZ-UHFFFAOYSA-N 0.000 description 1
- IDUZNWHHEUJEBT-UHFFFAOYSA-N 2H-indeno[1,2-d][1,3]thiazole Chemical compound C1=CC=C2C3=NCSC3=CC2=C1 IDUZNWHHEUJEBT-UHFFFAOYSA-N 0.000 description 1
- KGWNRZLPXLBMPS-UHFFFAOYSA-N 2h-1,3-oxazine Chemical group C1OC=CC=N1 KGWNRZLPXLBMPS-UHFFFAOYSA-N 0.000 description 1
- YHWMFDLNZGIJSD-UHFFFAOYSA-N 2h-1,4-oxazine Chemical group C1OC=CN=C1 YHWMFDLNZGIJSD-UHFFFAOYSA-N 0.000 description 1
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical group N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 description 1
- LHAMNQGGGDUVFZ-UHFFFAOYSA-N 3,4-dihydrodiazete Chemical compound C1CN=N1 LHAMNQGGGDUVFZ-UHFFFAOYSA-N 0.000 description 1
- LOOWMCWVRNEZLZ-UHFFFAOYSA-N 3-(1,3-dioxoisoindol-2-yl)propanenitrile Chemical compound C1=CC=C2C(=O)N(CCC#N)C(=O)C2=C1 LOOWMCWVRNEZLZ-UHFFFAOYSA-N 0.000 description 1
- KKSDPQGSPWRFLM-UHFFFAOYSA-N 3-(4h-indeno[1,2-d][1,3]thiazol-2-yl)-n,n-dimethylpropan-1-amine Chemical compound C1=CC=C2C(N=C(S3)CCCN(C)C)=C3CC2=C1 KKSDPQGSPWRFLM-UHFFFAOYSA-N 0.000 description 1
- UNIJBMUBHBAUET-UHFFFAOYSA-N 3-(methylamino)propanenitrile Chemical compound CNCCC#N UNIJBMUBHBAUET-UHFFFAOYSA-N 0.000 description 1
- ANLQHFYDQPMDJY-UHFFFAOYSA-N 3-oxo-3-piperidin-1-ylpropanenitrile Chemical compound N#CCC(=O)N1CCCCC1 ANLQHFYDQPMDJY-UHFFFAOYSA-N 0.000 description 1
- FBMIKPMPNVWMDE-UHFFFAOYSA-N 3-oxo-3-piperidin-1-ylpropanethioamide Chemical compound NC(=S)CC(=O)N1CCCCC1 FBMIKPMPNVWMDE-UHFFFAOYSA-N 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XKTYXVDYIKIYJP-UHFFFAOYSA-N 3h-dioxole Chemical compound C1OOC=C1 XKTYXVDYIKIYJP-UHFFFAOYSA-N 0.000 description 1
- VORDNGFQVIFSBE-UHFFFAOYSA-N 4-(1,3-dioxoisoindol-2-yl)butanenitrile Chemical compound C1=CC=C2C(=O)N(CCCC#N)C(=O)C2=C1 VORDNGFQVIFSBE-UHFFFAOYSA-N 0.000 description 1
- WLZWRDJURXUELY-UHFFFAOYSA-N 4-(dimethylamino)butanenitrile;hydrochloride Chemical compound [Cl-].C[NH+](C)CCCC#N WLZWRDJURXUELY-UHFFFAOYSA-N 0.000 description 1
- WVNLUPHQJHSWGM-UHFFFAOYSA-N 4-(furan-2-yl)-2-(1-methylpyrrolidin-3-yl)-1,3-thiazole;oxalic acid Chemical compound OC(=O)C(O)=O.C1N(C)CCC1C1=NC(C=2OC=CC=2)=CS1 WVNLUPHQJHSWGM-UHFFFAOYSA-N 0.000 description 1
- DNHBZJPTXSALLZ-UHFFFAOYSA-N 4-morpholin-4-ylbutanenitrile Chemical compound N#CCCCN1CCOCC1 DNHBZJPTXSALLZ-UHFFFAOYSA-N 0.000 description 1
- FDCZUDLRWMQRDZ-UHFFFAOYSA-N 5-(1,3-dioxoisoindol-2-yl)pentanenitrile Chemical compound C1=CC=C2C(=O)N(CCCCC#N)C(=O)C2=C1 FDCZUDLRWMQRDZ-UHFFFAOYSA-N 0.000 description 1
- YQULIWXYFBKEMV-UHFFFAOYSA-N 5-methyl-2-(1-methylpyrrolidin-3-yl)-4,5-dihydrobenzo[e][1,3]benzothiazole;dihydrochloride Chemical compound Cl.Cl.N=1C=2C3=CC=CC=C3C(C)CC=2SC=1C1CCN(C)C1 YQULIWXYFBKEMV-UHFFFAOYSA-N 0.000 description 1
- JIAKIQWNYAZUJD-UHFFFAOYSA-N 6,7-dihydro-5h-quinolin-8-one Chemical compound C1=CN=C2C(=O)CCCC2=C1 JIAKIQWNYAZUJD-UHFFFAOYSA-N 0.000 description 1
- PWAHHUYVRBAPAB-UHFFFAOYSA-N 7-bromo-6,7-dihydro-5h-quinolin-8-one Chemical compound C1=CN=C2C(=O)C(Br)CCC2=C1 PWAHHUYVRBAPAB-UHFFFAOYSA-N 0.000 description 1
- CHNFMGSWPXVXIX-UHFFFAOYSA-N 7-fluoro-2-(1-methylpyrrolidin-3-yl)-4h-indeno[1,2-d][1,3]thiazole;dihydrochloride Chemical compound Cl.Cl.C1N(C)CCC1C(S1)=NC2=C1CC1=CC=C(F)C=C21 CHNFMGSWPXVXIX-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- ONVHKLBQACOXPY-UHFFFAOYSA-N C(C)(=S)NC1N(CCC1)CC1=CC=CC=C1 Chemical compound C(C)(=S)NC1N(CCC1)CC1=CC=CC=C1 ONVHKLBQACOXPY-UHFFFAOYSA-N 0.000 description 1
- AWMHRVHGKOFCNI-UHFFFAOYSA-N C(CCCC)OC(C(C)(C)C)OOCCC(C)C Chemical compound C(CCCC)OC(C(C)(C)C)OOCCC(C)C AWMHRVHGKOFCNI-UHFFFAOYSA-N 0.000 description 1
- RLJXMPJNFHBEMB-WLHGVMLRSA-N C(\C=C\C(=O)O)(=O)O.S1C=NC2=C1C=CC=C2 Chemical compound C(\C=C\C(=O)O)(=O)O.S1C=NC2=C1C=CC=C2 RLJXMPJNFHBEMB-WLHGVMLRSA-N 0.000 description 1
- HELXSFKTDLLTPF-UHFFFAOYSA-N C1(CCCC2=CC=CC=C12)=O.BrC1=C(C(=O)O)C=CC(=C1C(=O)O)C Chemical compound C1(CCCC2=CC=CC=C12)=O.BrC1=C(C(=O)O)C=CC(=C1C(=O)O)C HELXSFKTDLLTPF-UHFFFAOYSA-N 0.000 description 1
- AJSJTPSUDGLADY-UHFFFAOYSA-N C1SC=C=CS1 Chemical compound C1SC=C=CS1 AJSJTPSUDGLADY-UHFFFAOYSA-N 0.000 description 1
- 206010007026 Calculus urethral Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229910021590 Copper(II) bromide Inorganic materials 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 206010017886 Gastroduodenal ulcer Diseases 0.000 description 1
- 206010018045 Gastroptosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 238000006546 Horner-Wadsworth-Emmons reaction Methods 0.000 description 1
- 206010021333 Ileus paralytic Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 230000006181 N-acylation Effects 0.000 description 1
- QQXLDOJGLXJCSE-UHFFFAOYSA-N N-methylnortropinone Natural products C1C(=O)CC2CCC1N2C QQXLDOJGLXJCSE-UHFFFAOYSA-N 0.000 description 1
- VLWBFSJRWITOLN-UHFFFAOYSA-N N1=CC=CC2=CC=CC=C12.O1N=CC2=C1C=CC=C2 Chemical compound N1=CC=CC2=CC=CC=C12.O1N=CC2=C1C=CC=C2 VLWBFSJRWITOLN-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- AYDQIZKZTQHYIY-UHFFFAOYSA-N OC(=O)C1(C)CC(C(O)=O)=CC=C1 Chemical compound OC(=O)C1(C)CC(C(O)=O)=CC=C1 AYDQIZKZTQHYIY-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010051482 Prostatomegaly Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241001627955 Tetraodon lineatus Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- GHVZOJONCUEWAV-UHFFFAOYSA-N [K].CCO Chemical compound [K].CCO GHVZOJONCUEWAV-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- YCNZFPXXIWEFCF-UHFFFAOYSA-N alumane;sodium Chemical compound [Na].[AlH3] YCNZFPXXIWEFCF-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical class N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- XXRGLCKZBCIEKO-DLMDZQPMSA-N azocine Chemical compound C/1=C/C=C\N=C/C=C\1 XXRGLCKZBCIEKO-DLMDZQPMSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 150000005524 benzylchlorides Chemical class 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- ARUJJNVNLJPSDO-UHFFFAOYSA-N butanamide;hydrochloride Chemical compound Cl.CCCC(N)=O ARUJJNVNLJPSDO-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 description 1
- OQNGCCWBHLEQFN-UHFFFAOYSA-N chloroform;hexane Chemical compound ClC(Cl)Cl.CCCCCC OQNGCCWBHLEQFN-UHFFFAOYSA-N 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000002508 compound effect Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- VAARWAQHHDYTPC-UHFFFAOYSA-N cyanomethyl dihydrogen phosphate Chemical compound OP(O)(=O)OCC#N VAARWAQHHDYTPC-UHFFFAOYSA-N 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N cycloheptane Chemical compound C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- WJTCGQSWYFHTAC-UHFFFAOYSA-N cyclooctane Chemical compound C1CCCCCCC1 WJTCGQSWYFHTAC-UHFFFAOYSA-N 0.000 description 1
- 239000004914 cyclooctane Substances 0.000 description 1
- 230000020335 dealkylation Effects 0.000 description 1
- 238000006900 dealkylation reaction Methods 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- YRTMEEURRDTMST-UHFFFAOYSA-N diazetidine Chemical compound C1CNN1 YRTMEEURRDTMST-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N diisobutylaluminium hydride Substances CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- RIYVKHUVXPAOPS-UHFFFAOYSA-N dithiine Chemical compound S1SC=CC=C1 RIYVKHUVXPAOPS-UHFFFAOYSA-N 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 125000005949 ethanesulfonyloxy group Chemical group 0.000 description 1
- HCPOCMMGKBZWSJ-UHFFFAOYSA-N ethyl 3-hydrazinyl-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)NN HCPOCMMGKBZWSJ-UHFFFAOYSA-N 0.000 description 1
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 231100000029 gastro-duodenal ulcer Toxicity 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- SNWQUNCRDLUDEX-UHFFFAOYSA-N inden-1-one Chemical compound C1=CC=C2C(=O)C=CC2=C1 SNWQUNCRDLUDEX-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical group C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000003971 isoxazolinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 125000005905 mesyloxy group Chemical group 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- FMXOEQQPVONPBU-UHFFFAOYSA-N methylidene(dioxido)azanium Chemical compound [O-][N+]([O-])=C FMXOEQQPVONPBU-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- CFHIDWOYWUOIHU-UHFFFAOYSA-N oxomethyl Chemical compound O=[CH] CFHIDWOYWUOIHU-UHFFFAOYSA-N 0.000 description 1
- 230000004203 pancreatic function Effects 0.000 description 1
- 208000000689 peptic esophagitis Diseases 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- LIGACIXOYTUXAW-UHFFFAOYSA-N phenacyl bromide Chemical compound BrCC(=O)C1=CC=CC=C1 LIGACIXOYTUXAW-UHFFFAOYSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000000247 postprecipitation Methods 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical class [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
- HNSIGQAALCSPEV-UHFFFAOYSA-N tert-butyl n-[2-(4h-indeno[1,2-d][1,3]thiazol-2-yl)cyclohexyl]carbamate Chemical compound CC(C)(C)OC(=O)NC1CCCCC1C(S1)=NC2=C1CC1=CC=CC=C21 HNSIGQAALCSPEV-UHFFFAOYSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- DWCSXQCXXITVKE-UHFFFAOYSA-N triethyloxidanium Chemical class CC[O+](CC)CC DWCSXQCXXITVKE-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 201000009160 urethral calculus Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
以通式(I)表示的噻唑衍生物作为有效成分的5-HT3受体激动剂、可用作5-HT3受体激动剂的特定化合物及可用作中间体的特定的硫代甲酰胺衍生物,式中,A环:可被取代的苯环或5员或6员不饱和杂环;L1和L2:其中的一个为单键,另一个不存在或表示具有1-4个碳原子的亚烷基或具有2-5个碳原子的亚链烯基;R:上式表示的基团。
Description
技术领域
本发明涉及以噻唑衍生物为有效成分的5-HT3受体激动剂、新颖的噻唑衍生物及其药学上可接受的盐以及它们的中间体。
背景技术
本发明的化合物具有作为位于肠管神经系统或中枢神经系统的初级传入神经末端的神经元的5-羟色胺(5-HT)受体的有效的和选择性的激动剂的作用。本发明的化合物通过使乙酰胆碱从消化道的传出神经末端释出而显示其作用。已知对消化道的乙酰胆碱受体的刺激可使消化道运动亢进和改善消化道功能衰弱〔Goodman and Gilman’s The Pharmacological Basis of Therapeutics8th edition,p125,(1990),Pergamon Press〕。而且还知道,在中枢神经系统中,5-HT3受体存在于突触前部,对其刺激可抑制神经活动〔J.Neurosci.,11,1881(1991)〕。因此,5-HT3受体激动剂被认为特别对消化系统的功能障碍有用。
虽然迄今尚未发现对5-HT3受体具有选择性激动活性的化合物,然而,本发明者报道过公开在WO92/07849中的噻唑衍生物具有对5-HT3受体的选择性激动活性。
日本专利公开公报1987年第252780号公开了下式表示的化合物:
(详细定义参见该公报)
然而,该公报记载的化合物的茚并噻唑的2位被通过氮原子结合的取代基取代,与本发明的化合物结构不同。而且,该公报仅公开了抗溃疡作用,对5-HT3受体的选择性激动活性未作任何揭示。
(详细定义参见该公报)以及在EP0307141公报中,作为使用权利要求的有效成分,记载了下述通式表示的化合物
(详细使用参见该公报)。
本发明的药用组合物的有效成分化合物(I)(见后述)包含概括性地记载在上述公报中的化合物,但在上述公报中,仅记载了这些化合物在制造嗜中性白细胞产生的活性氧的抑制剂即胆碱激动性神经症药中的应用,对这些化合物显示5-HT3受体的选择性激动活性未作任何记载或提示。
发明的公开
本发明者在上述技术状况下对受体的激动活性进行了更深入的研究,着眼于与迄今作为5-HT3受体激动活性指标的von Bezold-Jarisch反射〔A.S.Paintal et al.,Physiol.Rev.,53,159(1973)〕独立的5-HT3受体激动活性指标,即着眼于通过5-HT3受体的5-HT的豚鼠离体结肠的收缩作用,开展了合成研究,结果发现,下述通式(I)表示的噻唑衍生物具有优异的5-HT3受体的激动活性,由此完成了本发明。
即,本发明涉及一种由通式(I)表示的噻唑衍生物或其药学上可接受的盐和药学上可接受的载体组成的5-HT3受体激动剂、以及通式(I)表示的噻唑衍生物或其药学上可接受的盐在制造对治疗临床症状源于5-HT3受体激动失调的患者有用的药剂中的应用、和一种通过给患者服用必要有效量的通式(I)表示的噻唑衍生物或其药学上可接受的盐来治疗临床症状源于5-HT3受体激动失调的疾病的方法。〔式中符号的定义如下:A环:可被一个或多个选自卤原子、低级烷基和低级烷氧基的取代基分别取代的下述环:
1)苯环,或
2)含有一个或多个选自氮原子、氧原子或硫原子的杂原子的5员或6员不饱和杂环;L1和L2:其中的一个为单键,另一个不存在或表示具有1-4个碳原子的亚烷基或具有2-5个碳原子的亚链烯基;R:下式表示的基团:L3:低级亚烷基;L4:单键或低级亚烷基;R1和R2:相同或不同,表示氢原子、低级烷基或氨基保护基;R3:氢原子、低级烷基、桥氧基或可被保护的氨基;R4:不存在或表示氢原子、低级烷基、芳烷基或氨基保护基;B环:可分别含有氧原子的下述单环或二环:
1)具有4-16个成环原子的含氮杂环,或
2)含1个不饱和键的具有4-16个成环原子的含氮杂环;D环:具有4-8个成环原子的饱和碳环。
但R中的氮原子可成为伴有取代基的季胺盐。〕
本发明药用组合物的有效成分化合物(I)或其药学上可接受的盐具有下述化学结构上的特征:通过特定的碳链或不通过特定的碳链,特定的胺类基团或环等结合在特定的3环稠合的噻唑或4位或5位被苯环或特定的不饱和杂环(苯环或特定的不饱和杂环可被进一步取代)取代的噻唑中的任何一个的2位上,并具有下述药理学上的特征:具有优异的以与von Bezold-Jarisch反射独立的、通过5-HT3受体的豚鼠离体结肠的收缩作用为指标的5-HT3受体激动活性。
1)苯环,或
2)含有一个或多个选自氮原子、氧原子或硫原子的杂原子的5员或6员不饱和杂环;L1和L2:其中的一个为单键,另一个不存在或表示具有1-4个碳原子的亚烷基或具有2-5个碳原子的亚链烯基;R:下式表示的基团:L3:低级亚烷基;L4:单键或低级亚烷基;R1和R2:相同或不同,表示氢原子、低级烷基或氨基保护基;R3:氢原子、低级烷基、桥氧基或可被保护的氨基;R4:不存在或表示氢原子、低级烷基、芳烷基或氨基保护基;B环:可含有氧原子的下述单环或二环:
1)具有4-16个成环原子的含氮杂环,或
2)含1个不饱和键的具有4-16个成环原子的含氮杂环;D环:具有4-8个成环原子的饱和碳环。
但当A环为苯环或吡啶环时,L1和L2中的一个表示单键,另一个表示具有1-4个碳原子的亚烷基或具有2-5个碳原子的亚链烯基。另外,R中的氮原子可成为伴有取代基的季胺盐。〕
通式(II)表示的化合物或其药学上可接受的盐未被上述日本专利公开公报1993年51318号具体公开,可以说,它们被认为是从已具体公开的技术中无法自然推导出来的新颖化合物。
即,本发明化合物(II)具有下述化学结构上的特征:通过特定的碳链或不通过特定的碳链,特定的胺类基团或环等结合在特定的3环稠合的噻唑或4位或5位被吡啶环以外的特定的不饱和杂环(特定的不饱和杂环可被进一步取代)取代的噻唑中的任何一个的2位上。
本发明还包括对制造上述通式(I)、(II)或它们的药学上可接受的盐特别有用的中间体,并涉及选自(1-苄基-3-吡咯烷)硫代甲酰胺、(1-苄基-吡咯烷)硫代乙酰胺、1-氮杂二环〔2.2.1〕庚-4-硫代甲酰胺、1-甲基-2-吡咯烷酮-4-硫代甲酰胺和1-氮杂二环〔3.3.0〕辛烷-3-硫代甲酰胺或其盐。
下面对本发明作详细说明。
在本说明书的通式的定义中,若无特别说明,“低级”一词表示碳原子数为1-6个的直链或支链碳链。
因此,“低级烷基”的具体例子包括甲基、乙基、丙基、异丙基、丁基、异丁基、仲丁基、叔丁基、戊基、异戊基、新戊基、叔戊基、1-甲基丁基、2-甲基丁基、1,2-二甲基丙基、己基、异己基、1-甲基戊基、2-甲基戊基、3-甲基戊基、1,1-二甲基丁基、1,2-二甲基丁基、2,2-二甲基丁基、1,3-二甲基丁基、2,3-二甲基丁基、3,3-二甲基丁基、1-乙基丁基、2-乙基丁基、1,1,2-三甲基丙基、1,2,2-三甲基丙基、1-乙基-1-甲基丙基、1-乙基-2-甲基丙基等。其中优选C1-C4烷基,尤其优选C1-C3烷基。
L3或L4表示的“低级亚烷基”的具体例子包括亚甲基、亚乙基、甲基亚甲基、三亚甲基、1-甲基亚乙基、2-甲基亚乙基、四亚甲基、1-甲基三亚甲基、2-甲基三亚甲基、3-甲基三亚甲基、1-乙基亚乙基、2-乙基亚乙基、1,2-二甲基亚乙基、丙基亚甲基、五亚甲基、1-甲基四亚甲基、2-甲基四亚甲基、3-甲基四亚甲基、4-甲基四亚甲基、1-乙基三亚甲基、2-乙基三亚甲基、3-乙基三亚甲基、1,1-二甲基三亚甲基、2,2-二甲基三亚甲基、3,3-二甲基三亚甲基、六亚甲基、1-甲基五亚甲基、2-甲基五亚甲基、3-甲基五亚甲基、4-甲基五亚甲基、5-甲基五亚甲基、1,1-二甲基四亚甲基、4,4-二甲基四亚甲基等直链或支链的C1-C6亚烷基,其中优选直链或支链的C1-C4亚烷基,尤其优选C1-C3亚烷基。
L3和L4中的一个表示的“1-4个碳原子数的低级亚烷基”的具体例子包括上述“低级亚烷基”中碳原子数为1-4个的亚烷基,其中优选碳原子数为1-3个的亚烷基,尤其优选碳原子数为1-2个的亚烷基。
另外,“低级烷氧基”表示碳原子数为1-6个的直链或支链的烷氧基,具体例子包括甲氧基、乙氧基、丙氧基、异丙氧基、丁氧基、异丁氧基、仲丁氧基、叔丁氧基、戊氧基、异戊氧基、新戊氧基、叔戊氧基、1-甲基丁氧基、2-甲基丁氧基、1,2-二甲基丙氧基、己氧基、异己氧基、1-甲基戊氧基、2-甲基戊氧基、3-甲基戊氧基、1,1-二甲基丁氧基、1,2-二甲基丁氧基、2,2-二甲基丁氧基、1,3-二甲基丁氧基、2,3-二甲基丁氧基、3,3-二甲基丁氧基、1-乙基丁氧基、2-乙基丁氧基、1,1,2-三甲基丙氧基、1,2,2-三甲基丙氧基、1-乙基-1-甲基丙氧基、1-乙基-2-甲基丙氧基等。
尤其优选甲氧基、乙氧基、丙氧基、异丙氧基等,以甲氧基为最佳。
“芳烷基”表示上述“低级烷基”的任意氢原子被芳基如苯基、萘基等取代了的基团,具体的例子包括苄基、苯乙基、1-苯基乙基、3-苯基丙基、2-苯基丙基、1-苯基丙基、1-甲基-2-苯基乙基、4-苯基丁基、3-苯基丁基、2-苯基丁基、1-苯基丁基、2-甲基-3-苯基丙基、5-苯基戊基、4-苯基戊基、3-苯基戊基、2-苯基戊基、1-苯基戊基、3-甲基-4-苯基丁基、6-苯基己基、5-苯基己基、4-苯基己基、3-苯基己基、2-苯基己基、1-苯基己基、4-甲基-5-苯基戊基、1-萘基甲基、2-萘基甲基、2-(1-萘基)乙基、2-(2-萘基)乙基、1-(1-萘基)乙基、1-(2-萘基)乙基、3-(1-萘基)丙基、3-(2-萘基)丙基、2-(1-萘基)丙基、3-(2-萘基)丙基、1-(1-萘基)丙基、1-(2-萘基)丙基、1-甲基-2-(1-萘基)丙基、1-甲基2-(2-萘基)乙基、4-(1-萘基)丁基、4-(2-萘基)丁基、3-(1-萘基)丁基、3-(2-萘基)丁基、2-(1-萘基)丁基、2-(2-萘基)丁基、1-(1-萘基)丁基、1-(2-萘基)丁基、2-甲基3-(1-萘基)丙基、2-甲基-3-(2-萘基)丙基、5-(1-萘基)戊基、5-(2-萘基)戊基、4-(1-萘基)戊基、4-(2-萘基)戊基、3-甲基-4-(1-萘基)丁基、3-甲基-4-(2-萘基)丁基、6-(1-萘基)己基、6-(2-萘基)己基、5-(1-萘基)己基、5-(2-萘基)己基、4-甲基-5-(1-萘基)戊基、4-甲基-5-(2-萘基)戊基、二苯基甲基(二苯甲基)、三苯甲基等。
作为R1、R2和R4以及R3的“可被保护的氨基”中的氨基保护基所表示的氨基保护基的具体例子包括苄氧羰基、p-甲氧基苄氧羰基、p-甲基苄氧羰基、p-氯苄氧羰基、p-硝基苄氧羰基、p-苯基偶氮苄氧羰基、p-甲氧基苯基偶氮苄氧羰基、3,5-二甲氧基苄氧羰基、3,4,5-三甲氧基苄氧羰基等芳烷氧羰基;乙氧羰基、叔丁氧羰基、叔戊氧羰基等低级烷氧羰基;苯氧羰基等芳氧羰基;p-二苯基异丙氧羰基、二异丙基甲基氧羰基等其它尿烷型保护基;甲酰基、乙酰基、丙酰基、丁酰基、异丁酰基、戊酰基、异戊酰基、新戊酰基、己酰基等C1-C6链烷酰基;酰基类保护基如三氟乙酰基、邻苯二甲酰基、甲苯磺酰基、间-硝基苯亚磺酰基、对-甲氧基-间-硝基苯磺酰基、苯甲酰基、氯乙酰基等酰基;保护基和氨基的氮原子一起形成的邻苯二甲酰亚氨基等。
“卤原子”的例子包括氟原子、氯原子、溴原子、碘原子。
A环表示的环部分的“含有一个或多个选自氮原子、氧原子或硫原子的杂原子的5员或6员不饱和杂环”的具体例子包括吡咯环、吡唑环、咪唑环、吡啶环、嘧啶环、吡嗪环、哒嗪环等含氮的不饱和杂环;呋喃环、1,2-二氧杂环戊烯、1,3-二氧杂环戊烯、吡喃环、1,2-二噁二烯(dioxine)、1,3-二噁二烯、1,4-二噁二烯等含氧的不饱和杂环;噻吩环、1,2-二硫环戊二烯、1,3-二硫环戊二烯、噻喃环、1,2-二硫杂环己二烯、1,3-二硫杂环己二烯、1,4-二硫杂环己二烯等含硫的不饱和杂环;噁唑环、异噁唑环、噻唑环、异噻唑环、1,2-氧硫杂环戊二烯、1,3-氧硫杂环戊二烯、1,2-噁嗪环、1,3-噁嗪环、1,4-噁嗪环、1,2-噻嗪环、1,3-噻嗪环、1,4-噻嗪环、1,2-氧硫杂环己二烯、1,4-氧硫杂环己二烯等含有不同的2个杂原子的不饱和杂环以及在这些环中存在指示氢时指示氢的位置不同的结构同分异构的环。在下面的记述中,当杂原子的位置不同时,省略仅结合位置不同或指示氢的位置不同的环,但它们包括在下述环中。
其中,作为A环的杂环部分,优选吡啶环、呋喃环、噻吩环、噻唑环。
另外,B环表示的“可含有氧原子的单环或二环的具有4-16个成环原子的含氮饱和杂环”的较佳具体例子包括氮杂环丁烷、二氮杂环丁烷、吡咯烷、吡唑烷、咪唑烷、四氢三唑、哌啶环、哌嗪环、六氢三嗪环、六氢氮杂_、六氢二氮杂_、吖辛因、八氢吲哚环、八氢异吲哚环、八氢苯并吡唑环、十氢喹啉环、十氢异喹啉环、2,3-二氮杂十氢化萘、十氢喹喔啉环、十氢噌啉环、pyrrolididine(1-氮杂二环〔3.3.0〕辛烷)、奎宁环(1-氮杂二环〔2.2.2〕辛烷)、1-氮杂二环〔2.2.1〕庚烷、7-氮杂二环〔2.2.1〕庚烷、1-氮杂二环〔3.2.1〕辛烷、8-氮杂二环〔3.2.1〕辛烷、6-氮杂二环〔3.2.1〕辛烷、2-氮杂二环〔2.2.2〕辛烷、1-氮杂二环〔3.2.2〕壬烷、1-氮杂二环〔3.3.1〕壬烷、9-氮杂二环〔3.3.1〕壬烷、1-氮杂二环〔4.2.1〕壬烷、1-氮杂二环〔4.3.1〕癸烷、10-氮杂二环〔4.3.1〕癸烷、1-氮杂二环〔4.4.0〕癸烷、3,9-二氮杂二环〔3.3.1〕癸烷等含有1-2个以上(最好为1-3个)氮原子、可能缩合的、可能架桥的单环或二环的含氮饱和杂环;噁唑烷、异噁唑烷、吗啉、六氢氧氮杂_、八氢苯并噁唑啉、八氢苯并异噁唑啉、1-氮杂-3-氧杂双环〔2.2.2〕辛烷、9-氮杂-3-氧杂双环〔3.3.1〕壬烷等含有作为杂原子的氮原子和氧原子、可能缩合的、可能架桥的单环或二环的具有4-16个成环原子的含氮饱和杂环。
其中,作为B环表示的含氮饱和杂环,优选吡咯烷、哌啶环、哌嗪环、吗啉、1-氮杂二环〔3.3.0〕辛烷、奎宁环、1-氮杂二环〔2.2.1〕庚烷、8-氮杂二环〔3.2.1〕辛烷,尤其优选吡咯烷、、1-氮杂二环〔3.3.0〕辛烷、1-氮杂二环〔2.2.1〕庚烷。
另外,B环表示的“可含有氧原子的单环或二环的含1个不饱和键的具有4-16个成环原子的含氮杂环”的具体例子包括氮杂环丁烯、二氮杂环丁烯、吡咯啉环、吡唑啉环、咪唑啉环、二氢三唑啉环、四氢吡啶环、四氢吡嗪环、四氢三嗪环、四氢氮杂_、四氢二氮杂_、六氢吖辛因、六氢吲哚环、六氢异吲哚环、六氢苯并咪唑环、六氢苯并吡唑环、八氢喹啉环、八氢异喹啉环、2,3-二氮杂八氢化萘环、八氢喹喔啉环、八氢喹唑啉环、八氢噌啉环等含1个不饱和键的单环或二环的具有4-16个成环原子的含氮杂环;噁唑啉环、异噁唑啉环、二氢噁嗪环、六氢苯并噁唑啉环、六氢异噁唑啉环等含有氮原子和氧原子并含1个不饱和键的的单环或二环的具有4-16个成环原子的含氮杂环。所述这些环包括它们的双键位置不同的结构同分异构体。
其中,优选四氢吡啶环。
而D环表示的“具有4-8个成环原子的饱和碳环”的具体例子包括环丁烷、环戊烷、环己烷、环庚烷、环辛烷,其中优选环己烷。
本发明化合物(I)、(II)或它们的中间体可形成酸加合盐。本发明包括化合物(I)和(II)的药学上可接受的盐和中间体硫代甲酰胺类化合物的盐。这些盐的例子包括盐酸、氢溴酸、氢碘酸、硫酸、硝酸、磷酸等无机酸和甲酸、乙酸、丙酸、乙二酸、丙二酸、丁二酸、富马酸、马来酸、乳酸、苹果酸、柠檬酸、碳酸、甲磺酸、乙磺酸、天冬氨酸、谷氨酸等有机酸的酸加合盐。
这些化合物也可以是季铵盐。季铵盐的具体例子包括与低级烷基卤、三氟甲磺酸低级烷基酯、对甲苯磺酸低级烷基酯或苄基卤等反应而得的盐,优选与碘甲基或苄基氯等反应而得的盐。
在本发明化合物中,存在B环或D环的碳原子与L4结合的情况,并根据低级烷基链的种类,而存在含手性碳原子的光学异构体。另外,本发明化合物还存在由桥氧基的存在而产生的互变异构体、由架桥环的存在而产生的内(向)-外(向)异构的立体异构体等各种异构体。本发明包括这些异构体的分离出来的单体及它们的混合物。
另外,本发明化合物有时会作为水合物、乙醇合物等各种溶剂化物,或作为多晶型物质分离出来,本发明也包括这些物质。
在本发明药用组合物的有效成分化合物(I)中,尤其优选的是指定为(II)的化合物,它被认为是新的化合物。
另外,在本发明的化合物(II)中,尤其优选的化合物包括:(1)通式(IIa)表示的化合物(式中,A环、L3、R1和R2的定义同上,L1a和L2a中的一个表示单键,另一个表示碳原子数1-4个的亚烷基或碳原子数2-5个的亚链烯基。)(2)通式(IIb)表示的化合物(式中,A环、L1a、L2a、L3、B环和R3的定义同上。)(3)通式(IIc)表示的化合物(式中,A环、L1a、L2a、L4、B环、R3和R4的定义同上。)(4)通式(IId)表示的化合物(式中,A坏、L1a、L2a、L4、D环、R1和R2的定义同上。)、或(5)通式(IIe)表示的化合物(式中,L4、B环、R3和R4的定义同上,A1环表示可被一个或多个选自卤原子、低级烷基和低级烷氧基的取代基取代的、含一个或多个选自氮原子、氧原子、硫原子的杂原子的5员或6员不饱和杂环。但吡啶环除外。)
或者它们的药学上可接受的盐,更优选(6)通式(IIIa)表示的化合物(式中符号的定义如下:A2环:可被一个或多个选自卤原子、低级烷基和低级烷氧基的取代基取代的苯环;L2b:碳原子数1-4个的亚烷基;m:1-6的整数;R1a和R2b:相同或不同,表示氢原子或低级烷基。但R1a和R2b可和邻接的氮原子一起形成苯邻二甲酰亚氨基。)(7)通式(IIIb)表示的化合物(式中A2环和m的定义同上,其它符号的定义如下:L2c:碳原子数1-4个的亚烷基或亚乙烯基;R3a:氢原子、桥氧基或可被酰基保护的氨基;B1环:可有氧原子的单环或二环的具有4-8个成环原子的含氮饱和杂环。)(8)通式(IIIc)表示的化合物(式中A2环、L2b、R3a和B环的定义同上,其它符号的定义如下:R4a:不存在,或表示氢原子、低级烷基、芳烷基、低级烷氧羰基、芳烷氧基羰基、芳氧羰基或酰基;n:0或1-6的整数。)(9)通式(IIId)表示的化合物(式中A2环、L2b、n和D环的定义同上,R1a和R2b相同或不同,表示氢原子或低级烷基。)、或(10)通式(IIIe)表示的化合物(式中n和B1环的定义同上,其它符号的定义如下:A3环:含一个或多个选自氮原子、氧原子、硫原子的杂原子的5员或6员不饱和杂环,但吡啶环除外;R4b:氢原子、低级烷基或芳烷基。)
或它们的药学上可接受的盐,最优选的是上述化合物(IIIc)中B环为1-氮杂二环〔3.3.0〕辛烷环(pyrrolididine环)、1-氮杂二环〔2.2.1〕庚烷环或吡咯烷环的化合物或它们的药学上可接受的盐。
最佳化合物的具体例子包括:
(1)2-(3-吡咯烷基)-8H-茚并〔1,2-d〕噻唑
(2)(3R*,5S*)-3-(8H-茚并〔1,2-d〕噻唑-2-基)-1-氮杂二环〔3.3.0〕辛烷
(3)2-(3-吡咯烷基甲基)-8H-茚并〔1,2-d〕噻唑
(4)4-(8H-茚并〔1,2-d〕噻唑-2-基)-1-氮杂二环〔2.2.1〕庚烷
(5)(S)-2-(3-吡咯烷基)-8H-茚并〔1,2-d〕噻唑
(6)(3R,5S)-3-(8H-茚并〔1,2-d〕噻唑-2-基)-1-氮杂二环〔3.3.0〕辛烷
(7)(3S,5R)-3-(8H-茚并〔1,2-d〕噻唑-2-基)-1-氮杂二环〔3.3.0〕辛烷
(8)2-(1-甲基-3-吡咯烷基)-8H-茚并〔1,2-d〕噻唑
(9)5-〔(8H-茚并〔1,2-d〕噻唑-2-基)甲基〕-1-氮杂二环〔3.3.0〕辛烷或它们的药学上可接受的盐。
另外,本发明的有用中间体是选自(1-苄基-3-吡咯烷)硫代甲酰胺、(1-苄基-吡咯烷基)硫代乙酰胺、1-氮杂二环〔2.2.1〕庚烷-4-硫代甲酰胺、1-甲基-2-吡咯烷基-4-硫代甲酰胺和1-氮杂二环〔3.3.0〕辛烷-3-硫代甲酰胺之类的硫代甲酰胺衍生物或它们的盐,特别有用的中间体是具有1-氮杂二环〔3.3.0〕辛烷环、吡咯烷环的硫代甲酰胺或它们的盐。(制造方法)
本发明化合物(I)、(II)及它们的药学上可接受的盐可利用其由其基本骨架或取代基的种类而产生的特征,通过各种合成方法进行制造。此时,根据需要,将本发明化合物的氨基等用适当的保护基,即使用可容易地恢复成氨基等的官能团加以取代,作为一种制造技术有时是有效的。这类保护基的具体例子包括上述氨基保护基以及例如Greene和Wuts所著的“Protective Groups in OrganicSynthesis”(第2版)中记载的保护基。可根据反应条件合理使用这些保护基。其它如硝基等可容易地转化成氨基等的上述保护基以外的官能团也可和上述保护基一样加以利用。
下面举例说明本发明的代表性的制造方法。
本发明化合物(I)可按如下方法制备:将通式(IVa)或(IVb)所示α-卤代酮化合物与通式(IV)所示硫代甲酰胺化合物或其盐反应进行闭环,然后按需要除去保护基。
此处,X所示卤原子之例有碘、溴和氯原子。
有利的是,使反应在异丙醇、甲醇、乙醇等醇类溶剂或含水醇类溶剂等惰性有机溶剂中,用反应对应量的(IVa)或(IVb)与(V),或其中一种过量,在室温至加热下,最好是回流加热下进行。
保护基的除去因保护基种类而异,而每一种都可用常规方法进行。例如,在除去C1-C6链烷酰基或苯甲酰基等酰基型保护基的情况下,宜在酸或碱存在下进行水解,在除去取代或未取代的苄氧羰基的情况下,宜用接触还原,但可按情况用氢溴酸/乙酸、氢溴酸/三氟乙酸或氢氟酸进行酸处理。除去乙氧羰基或叔丁氧羰基等氨基甲酸乙酯型保护基则宜用氢溴酸/乙酸、三氟乙酸、盐酸、盐酸/乙酸、盐酸/二噁烷等进行酸处理。而在除去邻苯二甲酰基的情况下,宜用甲胺或肼进行处理。而且,可按常规方法用脱烷基反应除去烷基、芳烷基。
另外,原料化合物(V)可按一般方法从相应的酰胺进行制备,也可如下面的反应式所示,以相应的腈(VI)作为原料,在室温至加热下,使二硫代磷酸O,O-二烷酯或硫化氢等反应剂与之作用而制成。在二硫代磷酸酯起作用时,较好的是在乙酸乙酯等对反应惰性的有机溶剂中加入盐酸等的酸性条件下进行反应。在与硫化氢起作用时,较好的是在甲醇、乙醇等有机溶剂中,在氨、乙醇钠或乙醇钾存在下进行反应:
该反应的原料,即相应的腈化合物(VI),可按下面的反应式所示加以制备。例如,以相应的卤化物或磺酸酯(VII)作原料时,可在二甲亚砜等对反应惰性的有机溶剂中,用氰化钠等氰化剂与之作用进行制备。而以相应的氧代化合物(VIIIa)为原料时,在二噁烷等对反应惰性的有机溶剂中,最好在氢化钠等碱的存在下,用氰基甲基磷酸O,O-二烷酯等Horner-Emmons试剂进行处理,转化为氰基亚甲基衍生物(IX),在醇等有机溶剂中,对其进行用钯炭等作为催化剂的接触氢化等还原处理而制成。或者,将氧代化合物(VIIIb)作为原料,在二甲氧基乙烷等对反应惰性的有机溶剂中,在对甲苯磺酰基甲基胩等氰化剂及较好地在乙醇等醇的存在下,用卡丁醇钾等碱处理,也可制备腈化合物(VI)。又,以2-吡咯烷甲醇等具有羟烷基的仲胺(X)作为原料,在乙醇等对反应惰性的有机溶剂中,使丙烯腈等α,β-不饱和腈与之反应,生成氰基乙胺衍生物(XI),将其在甲苯等对反应惰性的有机溶剂中,在三乙胺等碱存在下,用甲磺酰氯等有机磺酸卤化物起作用,将羟基转变成活性基团,然后用叔丁醇钾等碱处理,产生闭环,也可制备含氮杂环腈化合物(VI)。也可用一般方法从相应的羧酸酰胺等羧酸衍生物(XII)制备腈化合物。(式中,R定义如上,其它符号定义如下:Y:卤原子或有机磺酸残基,R5a和R5b:与式
所示R相同的基团Z:羟基或羧酸衍生物残基。)
制法1的原料化合物(IVa)、(IVb)中也含新颖的化合物,可在醚、乙酸等有机溶剂中用溴、氯气、溴化铜(II)、全卤化物等卤化剂对相应的酮化合物作用而制成。
本发明化合物中通式(Ia)所示具有C-N键的杂环烷基噻唑衍生物可用通式(XIII)所示卤化物或磺酸与通式(XIVa)或(XIVb)所示胺类反应,需要时再除去保护基而制成。
此处,卤原子可列举前面所述的,有机磺酸残基可列举甲磺酰氧基和乙磺酰氧基等烷基磺酰氧基,以及苯磺酰氧基和甲苯磺酰氧基(特别是对甲苯磺酰氧基)等芳基磺酰氧基。
采用反应当量的化合物(XIII)和化合物(XIVa)或(XIIVb),或其中一方过量。在二甲基甲酰胺、二甲亚砜、乙醚、四氢呋喃、二噁烷、丙酮、甲乙酮、甲醇、乙醇、二氯甲烷、二氯乙烷或氯仿等惰性有机溶剂中,必要时在吡啶、甲基吡啶、二甲基苯胺、N-甲基吗啉、三甲胺、三乙胺、氢化钠、碳酸钾、碳酸钠、碳酸氢钠、氢化钠或氢氧化钾等碱的存在下,根据原料化合物,在冷却下至室温下,室温下至加热下或加热回流下进行反应。保护基的去除与制法1同样进行。
制法3(内酰胺或酰胺的还原) (式中,A环、L1、L2、L3、L4、B环和R4定义如前,R9表示氢原子或可被保护的氨基,L4表示C1-5亚烷基或C2-5亚链烯基,但是式表示具有内酰胺结构的含氮饱和杂环。)
本发明化合物中,通式(Ic)或(Ie)所示杂环烷基噻唑衍生物也可用相应的内酯(Ib)、(Id)或(If)还原而制成。
反应宜在四氢呋喃、乙醚、二噁烷、1,2-二甲氧乙烷、苯或甲苯等对反应惰性的溶剂中,采用反应当量或过量的氢化锂铝、氢化二(2-甲氧基乙氧基)铝钠或氢化二异丁基铝等还原剂,在低温至加热下,较好在加热回流下进行。或者,在氯化铵,乙酸等酸的存在下,或用四氟硼酸三乙基氧鎓盐或磷酰氯等处理后,用硼氢化钠作为还原剂对相应的内酰胺进行还原。
其它制备方法
在本发明化合物中,R1和R2中至少一个或R4为酰基型保护基、或R3为用保护基保护过的氨基的化合物,可通过用相应的氨基或其盐与相应的羧酸或其活性衍生物按常规进行N-酰化(酰胺化)而制成。
在本发明化合物中,R1和R2中至少一个或R4为低级烷基或芳烷基的化合物,可用相应的伯胺或仲胺衍生物作为原料,通过N-烷基化反应,与羰基化合物的还原烷基化反应,或N-酰化反应后的还原反应等而制成,N-烷基化反应可用相应的伯胺或仲胺衍生物、卤代烷或烷基磺酸盐,在与制法2同样的条件下进行。与羰基化合物的还原烷基化反应,可在二氯甲烷等对反应惰性的有机溶剂中,最好在乙酸等酸催化剂存在下,将相应的伯胺或仲胺衍生物用丙酮等羰基化合物和三乙酰氧基硼氢化钠或氰基硼氢化钠等适当的还原剂进行处理,或进行以钯碳等为催化剂的接触氢化等还原处理。也可用甲醛水和甲酸进行一般的还原甲基化反应。N-酰化后的还原反应可按常规方法将相应的胺与羧酸或其活性衍生物进行N-酰化后,在与制法3同样的条件下进行还原。
R的氮原子为季铵的化合物可将相应的叔胺与卤代烷等按常规方法反应而制成。
本发明化合物中,R为-L3-NR1R2或的化合物,可通过用常规方法还原相应的硝基取代的噻唑衍生物的硝基,然后接需要转换氮原子上的取代基而制成。
本发明的化合物中,B环为1,2,3,5-四氢吡啶环的化合物,可将相应的吡啶化合物与苄基卤等烷基化剂按常法反应生成吡啶鎓盐后,用硼氢化钠等适当的还原剂还原,根据需要转换氮原子上的取代基,从而制成。
也可将本发明的化合物中B环为具有1个不饱和键的含氮杂环的化合物作为原料,将其还原,制成相应的饱和杂环化合物。
这样制成的本发明化合物(I)每个均被分离、精制成游离化合物、成为其盐、水合物、溶剂化物等。本发明化合物(I)的制药学上容许的盐也可经通常的成盐反应而制成。
分离、精制可采用提取、分级结晶、重结晶、各种分级色谱法等常用的化学操作来进行。
利用异构体间的理化差异,可按常法分离各种异构体。例如,用一般的外消旋体拆分法〔如,用一般常用的旋光性酸(酒石酸)等将异构体转变成非对映异构的盐以进行光学拆分的方法等〕,可将外消旋化合物转变为立体化学纯的异构体。非对映异构体混合物可用常规方法,例如分级结晶或色谱法等,进行分离。
旋光性化合物也可用适当的旋光性原料化合物进行制备。
产业上的利用可能性
本发明化合物显示5-HT3受体激动活性,特别在豚鼠离体结肠的收缩作用上有显著作用。下面描述这种作用及其测定方法。
1)5-HT3受体激动活性
取出Hartley系雄性豚鼠(500-800g)的远端结肠,制成约20mm的切片。
将每条切片纵向悬挂在器官浴内,测定等长收缩反应。
5-HT在0.1-30μM的浓度内产生剂量依赖性的收缩反应,在10-30μM之间显示最大反应(5-HT的作用是介导5-HT3受体:J.Pharmacol.Exp.Ther.,259,15-21,1991)。
化合物的作用表示为在每个标本上与5-HT作用比较的相对值。
最大反应表示为以5-HT产生的最大收缩反应为100%时化合物产生的最大反应的百分率。
相对强度为以5-HT的EC50值作为基准(1)时化合物的EC50值相对值。
最大反应 | 相对强度 | |
实施例9化合物 | 75 | 1/2 |
实施例46化合物 | 52 | 1/2 |
实施例52化合物 | 77 | 22 |
实施例59化合物 | 45 | 1/3 |
实施例66化合物 | 57 | 144 |
实施例70化合物 | 23 | 4 |
实施例71化合物 | 51 | 2 |
(1)本发明化合物在300μM以下显示浓度依赖性的豚鼠离体结豚收缩作用。
本发明化合物中包含显示5-HT最大反应的70%以上作用的化合物,及在5-HT用量的1/2-1/100以下剂量显示收缩作用的化合物。
(2)本发明化合物的豚鼠离体结肠收缩作用受选择性5-HT3受体拮抗剂--特开平3-223278实施例44记载的化合物0.3μM的拮抗。
因此,确认本发明化合物的结肠收缩作用是通过5-HT3受体显示出来的。
从以上结果表明,本发明化合物是强的5-HT3受体激动剂。
2)促进大鼠排便作用
在Wistar系雄性大鼠(200g-300g)上研究了刺激5-HT3受体促进排便的使用(Miyata等.,J.Pharmacol.Exp.Ther.,261,297(1992))。对大鼠皮下投与化合物10mg/kg,测定投与后4小时的粪便数。
实施例52的化合物显示促进排便作用。
在本发明中还包含具有5-HT3受体拮抗作用的化合物,这样的化合物可视作本发明的另一种表现形式。这些化合物似乎在本发明者们关于四氢苯并咪唑衍生物的专利申请如特开平3-223278号公报上记载的医药用途上是有用的,这些医疗用途有例如抑制顺铂等抗癌药或放射线照射所引起的呕吐,预防和治疗偏头痛、复合头痛、三叉神经痛、焦虑症、胃肠运动障碍、消化性溃疡、过敏性肠综合征等。
本发明的化合物(I)或其盐、溶剂化物或水合物特异性地作用于肠神经元5-HT3受体,从而对于治疗消化系统障碍,即老年性、松弛型、直肠型等的便秘、急慢性胃炎、胃·十二指肠溃疡、胃神经官能症、胃下垂、返流性食道炎、假肠梗阻、非溃疡性消化不良、腹部不定疾患、糖尿病等疾患所佯有的消化道运动障碍、麻醉手术后消化道功能不全、胃内容物滞留、消化不良、鼓胀等,是有用的。还可用于脂肪吸收不全症等胰脏功能不全所伴有的疾患的治疗。
此外,本发明的化合物对于精神障碍(如精神分裂症和抑郁症)、焦虑、记忆障碍、疾呆、锥体外系障碍等症状的治疗也是有用的。
而且,本发明的化合物也可用于尿路闭塞、尿道结石或前列腺肥大等所伴有的排尿困难的治疗。
含有化合物的化合物作为有效成分的医药组合物,用常用的制剂用载体和赋形剂、其它添加剂,配制成片剂、散剂、细粒剂、颗粒剂、胶囊剂、丸剂、液体制剂、注射剂、栓剂、软膏、硬膏剂等,经口或非经口地投用。
本发明化合物对人的临床投用量在考虑被投用的患者的症状、体重、年龄和性别等后作出适当决定,通常成人经口投与0.1-100mg/天,一次或分数次投与。投用量因各种条件而异,但也有用比上述投用量范围少的量得到足够效果的情况。
作为按本发明的经口投与的固体组合物,可用片剂、散剂、颗粒剂等。对于这样的固体组合物,将一种或一种以上活性物质与至少一种惰性稀释剂,如乳糖,甘露醇、葡萄糖、羟丙基纤维素、微晶纤维素、淀粉、聚乙烯吡咯烷酮和硅酸铝酸镁,混合而成。接常规方法,组合物也可含有惰性稀释剂以外的添加剂,如硬脂酸镁之类润滑剂、纤维素乙醇酸钙之类崩解剂、乳糖之类稳定剂、谷氨酸或天冬氨酸之类增溶剂或溶解辅助剂。片剂或丸剂必要时也可用蔗糖、羟丙基纤维素、邻苯二甲酸羟丙基甲基纤维素酯等胃溶性或肠溶性物质的薄膜包衣。
经口投与的液体组合物包含药剂学上容许的乳剂、溶液剂、悬浮液、糖浆剂、酏剂等,含有常用的惰性稀释剂,如纯水和乙醇。此组合物除惰性稀释剂外还可含增溶剂或溶解辅助剂、湿润剂、悬浮剂之类辅助剂、甜味剂、调味剂、芳香剂和防腐剂。
非经口投与的注射剂包括,无菌水性或非水性的溶液剂、悬浮液、乳剂。水性溶液剂、悬浮液的稀释剂包括例如注射用蒸馏水和生理盐水。非水性溶液剂、悬浮液的稀释剂为例如聚丙二醇、聚乙二醇、橄榄油等植物油、乙醇等醇类和吐温80(商品名)等。这样的组合物还可再含有等渗剂、防腐剂、湿润剂、乳化剂、分散剂、稳定剂(如乳糖)、增溶剂或加溶剂之类的添加剂。它们可通过除菌滤器过滤、加入杀菌剂或辐照进行灭菌。它们也可制成无菌的固体组合物,使用前用无菌水或无菌注射用溶剂溶解后使用。
实施发明的最佳方式
以下揭示处方例、实施例,对本发明作更详细的说明。但是,不能认为本发明受这些实施例的限制。
另外,本发明的原料化合物中有些是新物质。原料化合物的制备用参考例表示。
处方例(片剂)
组成 20mg片剂
本发明化合物 20mg
乳糖 75
玉米淀粉 16
羟丙基纤维素 4.5
羧甲基纤维素钙 8.8
硬脂酸镁 0.7
共计 120mg
20mg片剂
将本发明化合物100g、乳糖375g、玉米淀粉80g用流动制粒包衣装置混合均匀。在其中喷雾10%羟丙基纤维素溶液225g,制粒。干燥后,通过20目筛,加入羧甲基纤维素钙19g、硬脂酸镁3.5g,混合,用旋转压片机,使用7mm×8.4R冲头,制成每片120mg的片剂。参考例1
将(S)-2-吡咯烷甲醇4.71g溶于乙醇13ml中,加入丙烯腈4.6ml,加热回流2小时。蒸去溶剂后,残渣溶于70ml甲苯中,在冰冷却下加入三乙胺13ml。向混合物中滴入甲磺酰氯4.3ml,在0℃搅拌10分钟,然后室温搅拌30分钟,加入叔丁醇钾15.7g,室温搅拌16小时。在反应液中加水,分取甲苯层,用无水硫酸钠干燥。蒸去溶剂,所得残渣经硅胶柱层析,从氯仿-甲醇-29%氨水(100∶10∶1)洗脱部分得到5.22g(5S)-1-氮杂二环〔3.3.0〕辛烷-3-腈,为非对映异构体混合物。质谱(m/z):136(M+)
(5R)-1-氮杂二环〔3.3.0〕辛烷-3-腈
原料化合物:(R)-2-吡啶烷甲醇
质谱(m/z):136(M+)参考例3
1-氮杂二环〔3.3.0〕辛烷-3-腈
原料化合物:(RS)-2-吡啶烷甲醇
1-氮杂二环〔4.4.0〕癸烷-3-腈
原料化合物:2-(2-羟基乙基)哌啶
质谱(m/z):164(M+)参考例5
在搅拌下,向氰化钠1.06g在二甲亚砜10ml的溶液中加入2-(2-氯乙基)-1-甲基吡咯烷盐酸盐2g在二甲亚砜10ml中的溶液,140℃加热搅拌6小时。加入碳酸氢钠水溶液,用氯仿萃取,分得的氯仿层用无水硫酸钠干燥。蒸去溶剂所得残渣经硅胶柱层析,从氯仿-甲醇-29%氨水(100∶10∶1)洗脱部分得到1.15g 3-(1-甲基-2-吡咯烷)丙腈,为油状物。
质谱(m/z):138(M+)
核磁共振谱(CDCl3,TMS内标)
δ.1.43-1.50(1H,m),1.61-1.80(3H,m),1.93-2.00(2H,m),2.17-2.50(4H,m),2.31(3H,s),3.06(1H,t)
与参考例5同样地得到参考例6-7的化合物。参考例6
(1-苄基-2-哌啶)乙腈
原料化合物:1-苄基-2-氯甲基哌啶盐酸盐
核磁共振谱(CDCl3,TMS内标)
3-(1-苄基-2-哌啶)丙腈
原料化合物:1-苄基-2-(2-氯乙基)哌啶盐酸盐
红外吸收谱νmax(KBr)cm-1:3076,3040,2948,2868,2808,2252,1498,1456,736,700
核磁共振谱(CDCl3,TMS内标)
将氰基甲基膦酸二乙酯1.95g在二噁烷40ml中的溶液冷却至10℃,在氩气氛围下加入氢化钠(60%)0.44g。再在同样的温度下滴加托品酮1.39g在二噁烷25ml中的溶液,室温下搅拌1.5小时。蒸去溶剂后,加水,用氯仿萃取,用无水碳酸钾干燥。蒸去溶剂后,得到1.66g 3-氰基亚甲基-8-氮杂二环〔3.2.1〕辛烷,为油状物。
质谱(m/z):162(M+)
红外吸谱νmax(NaCl)cm-1:2220(C≡N)
核磁共振谱(CDCl3,TMS内标)
δ:2.38(3H,s),5.17(1H,s)参考例9
向3-氰基亚甲基-8-甲基-8-氮杂二环〔3.2.1〕辛烷1.42g在甲醇50ml中的溶液加入10%钯炭0.80g,在1大气压的氢气流下室温搅拌72小时。滤去钯炭后,蒸去溶剂,所得残渣用硅胶柱层析提纯,洗脱剂为氯仿/甲醇/29%氨水,得到0.70g内-8-甲基-8-氮杂二环〔3.2.1〕辛烷-3-乙腈,为油状物。
质谱(m/z):164(M+)
红外吸收谱νmax(NaCl)cm-1:2252(C≡N)
核磁共振谱(CDCl3,TMS内标)
δ:1.40(2H,d),1.49-1.54(2H,m),2.09-2.11(2H,m),2.14-2.16(1H,m),2.20-2.24(2H,m),2.25(3H,s),2.46(2H,m),3.15(2H,s)参考例10
将7-氧代-4,5,6,7-四氢苯并呋喃1.09g溶于乙醚100ml中,加入溴0.41ml,室温搅拌1小时。蒸去溶剂,残渣进行硅胶柱层析,从己烷-乙酸乙酯(10∶1)洗脱部分得到1.13g 6-溴-7-氧代-4,5,6,7-四氢苯并呋喃,为油状物。
质谱(m/z):214,216(M+)
核磁共振谱(CDCl3,TMS内标)
向8-氧代-5,6,7,8-四氢喹啉0.68在乙酸25ml溶液中加入25%氢溴酸乙酸溶液2.5ml,滴加溴0.235ml。室温下搅拌30分钟后,蒸去溶剂,所得残渣用乙醚洗净,得到1.5g 7-溴-8-氧代-5,6,7,8-四氢喹啉氢溴酸盐。
质谱(m/z):225,227(M+)
核磁共振谱(DMSO-d6,TMS内标)
将苯二甲酰亚氨基乙腈3.07g溶于4N氯化氢/乙酸乙酯溶液20ml中,在该溶液中加入二硫代磷酸O,O-二乙酯3.17ml,室温搅拌6小时。滤取生成的沉淀,用乙酸乙酯和乙醚相继洗涤,得到苯二甲酰亚氨基硫代乙酰胺2.29g。
质谱(m/z):220(M+)
核磁共振谱(DMSO-d6,TMS内标)
δ:4.46(2H,s),7.85-7.98(4H,m),9.44(1H,br),9.76(1H,br)
3-苯二甲酰亚氨基硫代丙酰胺
原料化合物:3-苯二甲酰亚氨基丙腈
质谱(m/z):234(M+)
核磁共振谱(DMSO-d6,TMS内标)
δ:2.34(2H,t),3.92(2H,t),7.85(4H,s),9.37(2H,br)参考例14
4-苯二甲酰亚氨基硫代丁酰胺
原料化合物:4-苯二甲酰亚氨基丁腈
质谱(m/z):248(M+)
核磁共振谱(DMSO-d6,TMS内标)
5-苯二甲酰亚氨基硫代戊酰胺
原料化合物:5-苯二甲酰亚氨基戊腈
质谱(m/z):262(M+)
核磁共振谱(DMSO-d6,TMS内标)
6-苯二甲酰亚氨基硫代己酰胺
原料化合物:4-苯二甲酰亚氨基己腈
质谱(m/z):276(M+)
核磁共振谱(DMSO-d6,TMS内标)
3-二甲氨基硫代丙酰胺盐酸盐
原料化合物:3-二甲氨基丙腈
4-二甲氨基硫代丁酰胺盐酸盐
原料化合物:4-二甲氨基丁腈盐酸盐
3-二乙氨基硫代丙酰胺盐酸盐
原料化合物:3-二乙氨基丙腈
质谱(m/z):161(M++1)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.25(6H,t),3.05-3.48(8H,m),9.70(2H,br)参考例20
4-(1-吡咯烷)硫代丁酰胺盐酸盐
原料化合物:4-(1-吡咯烷)丁腈
核磁共振谱(DMSO-d6,TMS内标)
4-吗啉代硫代丁酰胺盐酸盐
原料化合物:4-吗啉代丁腈
质谱(m/z):189(M++1)
核磁共振谱(DMSO-d6,TMS内标)
(1-乙氧羰基-4-哌啶)硫代乙酰胺盐酸盐
原料化合物:(1-乙氧羰基-4-哌啶)乙腈
熔点:109-111℃乙醚
质谱(m/z):231(M+)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.10-1.21(2H,m),1.25(3H,t),1.79(2H,d),2.13-2.24(1H,m),2.53(2H,d),2.78(2H,t),4.09-4.20(4H,m)参考例23
(1-苄基-3-哌啶)硫代乙酰胺盐酸盐
原料化合物:(1-苄基-3-哌啶)乙腈
质谱(m/z):249(M++1)
(1-苄基-3-吡咯烷)硫代甲酰胺盐酸盐
原料化合物:(1-苄基-3-吡咯烷)腈
熔点:195-199℃乙酸乙酯-甲醇
质谱(m/z):220(M+)
核磁共振谱(DMSO-d6,TMS内标)
δ:2.00-2.20(1H,m),2.23-2.42(1H,m),3.18-3.27(1H,m),3.39-3.72(4H,m),4.35-4.45(2H,m),7.43-7.44(3H,m),7.64-7.66(2H,m)参考例25
(1-苄基-2-吡咯烷)硫代乙酰胺盐酸盐
原料化合物:(1-苄基-2-吡咯烷)乙腈
质谱(m/z):235(M++1)
核磁共振谱(DMSO-d6,TMS内标)
(1-苄基-3-吡咯烷)硫代乙酰胺盐酸盐
原料化合物:(1-苄基-3-吡咯烷)乙腈
质谱(m/z):234(M+)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.61-1.76(1H,m),2.07-2.29(1H,m),2.60-3.45(7H,m),4.33-4.36(2H,m),7.43-7.44(3H,m),7.60-7.64(2H,m)参考例27
〔(S)-1-〔(R)-1-苯乙基〕-3-吡咯烷〕硫代乙酰胺盐酸盐
原料化合物:〔(S)-1-〔(R)-1-苯乙基〕-3-吡咯烷〕乙腈
质谱(m/z):249(M++1)参考例28
〔(R)-1-〔(R)-1-苯乙基〕-3-吡咯烷〕硫代乙酰胺盐酸盐
原料化合物:〔(R)-1-〔(R)-1-苯乙基〕-3-吡咯烷〕乙腈
3-(1-甲基-2-吡咯烷)硫代丙酰胺盐酸盐
原料化合物:3-(1-甲基-2-吡咯烷)丙腈
外-8-甲基-8-氮杂二环〔3.2.1〕辛烷-3-硫代甲酰胺盐酸盐
原料化合物:外-8-甲基-8-氮杂二环〔3.2.1〕辛烷-3-腈
熔点:225-230℃(分解)乙酸乙酯-甲醇
核磁共振谱(DMSO-d6,TMS内标)
内-8-甲基-8-氮杂二环〔3.2.1〕辛烷-3-硫代乙酰胺盐酸盐
原料化合物:内-8-甲基-8-氮杂二环〔3.2.1〕辛烷-3-乙腈
熔点:230-233℃乙酸乙酯-甲醇
质谱(m/z):89(M+)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.44-1.66(2H,m),1.99-2.04(2H,m),2.19-2.21(2H,m),2.38-2.43(2H,m),2.46-2.48(1H,m),2.59-2.61(3H,m),2.69-2.75(2H,m),3.67-3.76(2H,m)参考例32
1-氮杂〔2.2.1〕庚烷-4-硫代甲酰胺盐酸盐
原料化合物:1-氮杂〔2.2.1〕庚烷-4-腈
质谱(m/z):157(M++1)
核磁共振谱(DMSO-d6,TMS内标)
(4R*,5R*)-1-氮杂二环〔3.3.1〕壬烷-4-硫代甲酰胺
原料化合物:(4R*,5R*)-1-氮杂二环〔3.3.1〕壬烷-4-腈
质谱(m/z):185(M++1)
核磁共振谱(CDCl3,TMS内标)
δ:2.66(2H,s)参考例34
(1-甲基-3-吡咯烷)硫代甲酰胺盐酸盐
原料化合物:(1-甲基-3-吡咯烷)腈
熔点119-123℃乙酸乙酯-甲醇
质谱(m/z):145(M++1)
核磁共振谱(DMSO-d6,TMS内标)
(1-苄基-2-哌啶)硫代乙酰胺盐酸盐
原料化合物:(1-苄基-2-哌啶)乙腈
质谱(m/z):248(M+)参考例36
3-(1-苄基-2-哌啶)硫代丙酰胺盐酸盐
原料化合物:3-(1-苄基-2-哌啶)丙腈
质谱(m/z):2 63(M++1)
红外吸收谱vmax(KBr)cm-1:1636,1458,1424,702参考例37
3-(1-硝基环己基)硫代丙酰胺
原料化合物:3-(1-硝基环己基)丙腈
质谱(m/z):216(M+)
核磁共振谱(CDCl3,TMS内标)
δ:1.20-2.00(8H,m),2.20-2.60(6H,m)参考例38
(哌啶基羰基)硫代乙酰胺
原料化合物:(哌啶基羰基)乙腈
质谱(m/z):186(M+)
核磁共振谱(CDCl3,TMS内标)
δ:4.14(2H,s)参考例39
1-甲基-2-吡咯烷酮-4-硫代甲酰胺
原料化合物:1-甲基-2-吡咯烷酮-4-腈
熔点:127-133℃乙酸乙酯-甲醇
将4-吡啶硫代乙酰胺盐酸盐1.95g和2-溴-1-二氢茚酮1.8g溶于异丙醇100ml中,加入碳酸钙2g后,加热回流5小时。冷却后,滤去不溶物,蒸去溶剂。在残渣中加入乙酸乙酯和1N盐酸,分取水层,用碳酸氢钠中和后用氯仿萃取。分取氯仿层,用无水硫酸钠干燥,蒸去溶剂,所得残渣经硅胶柱层析,从氯仿——甲醇——29%氨水(100∶10∶1)洗脱部分得到1.54g 2-(4-吡咯基甲基)-8H-茚并〔1,2-d〕噻唑,为油状物。
质谱(m/z):264(M+)
核磁共振谱(CDCl3,TMS内标)
δ:3.80(2H,s),4.43(2H,s),7.26-7.84(6H,m),8.53-8.68(2H,m)
与参考例40同样地得到参考例41-43的化合物。参考例41
2-(3-吡啶基甲基)-8H-茚并〔1,2-d〕噻唑
原料化合物:2-溴-1-二氢茚酮,3-吡啶硫代乙酰胺盐酸盐
熔点112-113℃乙酸乙酯
质谱(m/z):264(M+)
核磁共振谱(CDCl3,TMS内标)
δ:3.79(2H,s),4.43(2H,s),7.25-7.28(2H,m),7.39(1H,d),7.48(1H,d),7.69(1H,d),7.74(1H,d),8.54(1H,dd),8.65(1H,d)参考例42
2-〔2-(1-硝基环己基)乙基〕-8H-茚并〔1,2-d〕噻唑
原料化合物:2-溴-1-二氢茚酮,3-(1-硝基环己基)硫代丙酰胺
质谱(m/z):329(M++1)
核磁共振谱(CDCl3,TMS内标)
2-〔(哌啶子基羰基)甲基〕-8H-茚并〔1,2-d〕噻唑
原料化合物:2-溴-1-二氢茚酮,(哌啶子基羰基)硫代乙酰胺
熔点:127-129℃乙酸乙酯-己烷
质谱(m/z):298(M+)
核磁共振谱(CDCl3,TMS内标)
δ:1.50-1.70(6H,m),3.57(2H,t,J=5.5Hz),3.61(2H,t,J=5.5Hz),3.83(2H,s),4.25(2H,s),7.25(1H,t,J=7.0Hz),7.37(1H,t,J=7.0Hz),7.49(1H,d,J=7.0Hz),7.76(1H,d,J=7.0Hz)参考例44
向1-氮杂二环〔3.3.1〕壬-4-酮2.00g在二甲氧基乙烷100ml中的溶液加入对甲苯磺酰甲基异氮酸酯3.65g、乙醇1.13g,冷却于5℃。在内部温度不超过10℃下,加入叔丁醇钾4.00g。室温搅拌30分钟,再于40℃搅拌30分钟。滤去生成的沉淀后,浓缩滤液,用氧化铝柱层析(洗脱液∶氯仿-己烷=1∶1)精制后,再将所得的粗产物用硅胶柱层析(洗脱液∶氯仿∶甲醇=20∶1)精制,得到(4R*,5R*)-1-氮杂二环〔3.3.1〕壬-4-腈1.01g。
质谱(m/z):150(M+)
核磁共振谱(CDCl3,TMS内标)
在饱和氨-甲醇溶液30ml中,溶解3-哌啶腈6.4g(58mmol),在保持10-15℃下通入硫化氢气体至饱和。保持在密闭条件下,室温搅拌2天后,减压蒸干。将残渣先在甲醇-异丙醇中,然后在水中,进行重结晶,得到(3-哌啶)硫代甲酰胺0.5g,为结晶体。
熔点:223-226℃,水
质谱(m/z):144(M+)参考例46
将6-氮杂二环〔3.2.0〕庚-7-酮2.8g溶于四氢呋喃60ml中,加入Lawes-son′s试剂10.2g,加热回流3小时。蒸去溶剂,所得残渣进行硅胶柱层析,从己烷——乙酸乙酯(4∶1)洗脱部分得到0.78g 6-氮杂二环〔3.2.0〕庚-7-硫酮,为结晶体。
熔点:67-70℃己烷-乙酸乙酯
质谱(m/z):127(M+)
核磁共振谱(CDCl3:TMS内标)
δ:1.37-1.54(2H,m),1.74-1.94(3H,m),2.06(1H,dd),3.48(1H,d),4.55(1H,t),7.80(1H,br)
7-氮杂二环〔4.2.0〕辛-8-硫酮
原料化合物:7-氮杂二环〔4.2.0〕辛-8-酮
质谱(m/z):141(M+)
核磁共振谱(CDCl3,TMS内标)
将6-氮杂二环〔3.2.0〕庚-7-硫酮0.82g溶于二氯甲烷50ml中,依次加入三乙胺0.90ml、二甲氨基吡啶0.79g、焦碳酸二叔丁酯2.81g,室温下搅拌10分钟。蒸去溶剂,所得残渣进行硅胶柱层析,从己烷-乙酸乙酯(2∶1)洗脱部分得到1.48g 6-叔丁氧羰基-6-氮杂二环〔3.2.0〕庚-7-硫酮,为结晶体。
熔点:86-88℃己烷-乙酸乙酯
质谱(m/z):227(M+)
核磁共振谱(CDCl3,TMS内标)
δ:1.41-1.58(2H,m),1.54(9H,s),1.64-1.72(1H,m),1.84-1.90(1H,m),2.08(1H,dd),2.22(1H,dd),3.31(1H,dd),4.78(1H,t)
7-叔丁氧羰基-7-氮杂二环〔4.2.0〕辛-8-硫酮
原料化合物:7-氮杂二环〔4.2.0〕辛-8-硫酮
质谱(m/z):241(M+)
核磁共振谱(CDCl3,TMS内标)
δ:1.26-2.10(8H,m),1.55(9H,s),3.03-3.07(1H,m),4.60(1H,dd)参考例50
将6-叔丁氧羰基-6-氮杂二环〔3.2.0〕庚-7-硫酮1.48g溶于29%氨水42ml、甲醇60ml中,室温搅拌30分钟。用苯-乙醇共沸蒸去溶剂,得到1.39g 2-(叔丁氧羰基氨基)环戊烷硫代甲酰胺结晶。
熔点:162-164℃
质谱(m/z):245(M++1)
核磁共振谱(CDCl3,TMS内标)
δ:1.44(9H,s),47-2.39(6H,m),2.38(1H,br),3.27-3.33(1H,m),4.11-4.19(1H,m)
与参考例50同样地得到参考例51的化合物。参考例51
2-(叔丁氧羰基氨基)环己基硫代甲酰胺
原料化合物:7-叔丁氧羰基-7-氮杂二环〔4.2.0〕辛-8-硫酮
熔点:178-180℃己烷-乙酸乙酯
质谱(m/z):258(M+)
核磁共振谱(CDCl3,TMS内标)
δ:1.23-2.14(8H,m),1.43(9H,s),2.77(1H,br),4.23(1H,br)实施例1
将2-溴-1-二氢茚酮1.64g溶于异丙醇100ml中,在溶液中加入苯二甲酰亚氨基硫代乙酰胺2.0g,加热回流6小时。滤取生成的沉淀。将其分配于氯仿和饱和碳酸氢钠水溶液。分取有机层,用水、饱和氯化钠水溶液相继洗涤后,用无水硫酸钠干燥,蒸去溶剂,得到2-苯二甲酰亚氨基甲基-8H-茚并〔1,2-d〕噻唑1.3g。
质谱(m/z):332(M+)
核磁共振谱(CDCl3,TMS内标)
δ:3.79(2H,s),5.29(2H,s),7.20-7.51(4H,m),7.70-7.98(4H,m)
2-(2-苯二甲酰亚氨基乙基)-8H-茚并〔1,2-d〕噻唑
原料化合物:
2-溴-1-二氢茚酮,3-苯二甲酰亚氨基硫代丙酰胺
质谱(m/z):346(M+)
核磁共振谱(CDCl3,TMS内标)
δ:3.49(2H,t),3.78(2H,s),4.18(2H,t),7.19-7.90(8H,m)实施例3
2-(3-苯二甲酰亚氨基丙基)-8H-茚并〔1,2-d〕噻唑
原料化合物:
2-溴-1-氯茚酮,4-苯二甲酰亚氨基硫代丁酰胺
质谱(m/z):360(M+)
核磁共振谱(CDCl3,TMS内标)
2-(4-苯二甲酰亚氨基乙基)-8H-茚并〔1,2-d〕噻唑
原料化合物:
2-溴-1-二氢茚酮,5-苯二甲酰亚氨基硫代戊酰胺
质谱(m/z):374(M+)
核磁共振谱(CDCl3,TMS内标)
δ:1.74-1.83(4H,m),3.05-3.28(2H,m),3.70-3.77(2H,m)3.78(2H,s),7.69-7.80(8H,m)实施例5
2-(5-苯二甲酰亚氨基乙基)-8H-茚并〔1,2-d〕噻唑
原料化合物:
2-溴-1-二氢茚酮,6-苯二甲酰亚氨基硫代己酰胺
质谱(m/z):388(M+)
核磁共振谱(CDCl3,TMS内标)
δ:1.41-1.95(6H,m),3.02(2H,t),3.70(2H,t),3.77(2H,s),7.64-7.90(8H.m)实施例6
2-〔(1-乙氧羰基-4-哌啶基)甲基〕-8H-茚并〔1,2-d〕噻唑
原料化合物:
2-溴-1-二氢茚酮,(1-乙氧羰基-4-哌啶基)硫代乙酰胺
质谱(m/z):342(M+)
核磁共振谱(CDSO-d6,TMS内标)
δ:1.11-1.21(5H,m),1.69(2H,d),1.94-2.01(1H,m),3.01(2H,d),3.09(2H,s),3.94-4.04(4H,m),7.25(1H,t),7.36(1H,t),7.56(1H,d),7.63(1H,d)实施例7
2-(1-甲基-2-氧-4-吡咯烷基)-8H-茚并〔1,2-d〕噻唑
原料化合物:
2-溴-1-二氢茚酮,1-甲基-2-吡咯烷酮-4-硫代甲酰胺
熔点:114-116℃
质谱(m/z):270(M+)
核磁共振谱(DMSO-d6,TMS内标)
δ:2.64(1H,dd),2.79(3H,s),2.85(1H,dd),3.88(1H,dd),3.94(2H,s),4.09-4.15(1H,m),7.28(1H,t),7.38(1H,t),7.59(1H,d),7.66(1H,d)实施例8
向2-溴甲基萘并〔1,2-d〕噻唑0.14g和3-乙酰氨基吡咯烷0.10g在乙醇7ml的溶液中,加入碳酸钾0.14g,加热回流1小时。蒸去溶剂,在所得残渣中加入,用氯仿萃取,用无水硫酸镁干燥。蒸去溶剂,所得残渣中加乙醚产生结晶,得到0.13g 2-〔(3-乙酰氨基-1-吡咯烷基)甲基〕萘并〔1,2-d〕噻唑。
将2-(2-苯二甲酰亚氨基乙基)-8H-茚并〔1,2-d〕噻唑1.79g溶于甲醇20ml中,加入40%甲胺的甲醇溶液40ml,室温搅拌14小时。蒸去溶剂,所得残渣中加入氯仿和1N盐酸,分取水层,用1N氢氧化钠水溶液中和后,用氯仿萃取。将分取的氯仿层用水、饱和氯化钠水溶液相继洗涤后,用无水硫酸钠干燥。蒸去溶剂,将所得残渣溶于甲醇,在溶液中加富马酸,滤取生成的结晶,用甲醇、乙醚相继洗涤后,用甲醇重结晶,得到2-(2-氨基乙基)-8H-茚并〔1,2-d〕噻唑富马酸盐572mg。
熔点:208-210℃
元素分析值(以C12H12N2S·C4H4O4计)
C(%) H(%) N(%) S(%)
理论值 57.82 4.85 8.48 9.65
实验值 57.48 4.91 8.38 9.62
质谱(m/z):216(M+)
核磁共振谱(DMSO-d6,TMS内标)
δ:3.23(2H,t),3,36(2H,t),3,92(2H,s),6,45(2H,s),7.27(1H,t),7.37(1H,t),7.57(1H,d),7.66(1H,d)
2-氨基甲基-8H-茚并〔1,2-d〕噻唑富马酸盐
原料化合物:
2-苯二甲酰亚氨基甲基-8H-茚并〔1,2-d〕噻唑
熔点:184-1 86℃甲醇
元素分析值(以C11H10N2S·C4H4O4·0.1H2O计)
C(%) H(%) N(%) S(%)
理论值 56.27 4.47 8.75 10.02
实验值 56.12 4.45 8.62 10.12
质谱(m/z):202(M+)
核磁共振谱(DMSO-d6,TMS内标)
2-(3-氨基丙基)-8H-茚并〔1,2-d〕噻唑富马酸盐
原料化合物:
2-(3-苯二甲酰亚氨基丙基)-8H-茚并〔1,2-d〕噻唑
熔点:178-180℃甲醇
元素分析值(以C13H14N2S·C4H4O4计)
C(%) H(%) N(%) S(%)
理论值 58.94 5.24 8.09 9.26
实验值 58.73 4.17 8.05 9.20
质谱(m/z):230(M+)
核磁共振谱(DMSO-d6,TMS内标)
δ:2.03-2.11(2H,m),2.90(2H,t),3.17(2H,t),3.91(2H,s),6.42(2H,s),7.26(1H,t),7.37(1H,t),7.56(1H,d),7.63(1H,d)实施例12
2-(4-氨基丁基)-8H-茚并〔1,2-d〕噻唑富马酸盐
原料化合物:
2-(4-苯二甲酰亚氨基丁基)-8H-茚并〔1,2-d〕噻唑
熔点:183-186℃甲醇
元素分析值(以C14H16N2S·C4H4O4计)
C(%) H(%) N(%) S(%)
理论值 59.68 5.62 7.73 8.85
实验值 59.50 5.73 7.62 8.87
质谱(m/z):244(M+)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.62-1.70(2H,m),1.80-1.87(2H,m),2.82(2H,t),3.10(2H,t),3.90(2H,s),6.41(2H,s),7.25(1H,t),7.36(1H,t),7.56(1H,d),7.62(1H,d)实施例13
2-(5-氨基戊基)-8H-茚并〔1,2-d〕噻唑富马酸盐
原料化合物:
2-(5-苯二甲酰亚氨基戊基)-8H-茚并〔1,2-d〕噻唑
熔点:184-186℃甲醇
元素分析值(以C15H18N2S·C4H4O4计)
C(%) H(%) N(%) S(%)
理论值 60.65 5.95 7.45 8.52
实验值 60.44 5.81 7.33 8.54质谱(m/z):258(M+)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.43-1.44(2H,m),1.58-1.62(2H,m),1.58-1.82(2H,m),2.78(2H,t),3.07(2H,t),3.90(2H,s),6.44(2H,s),7.25(1H,t),7.36(1H,t),7.56(1H,d),7.62(1H,d)实施例14
将2-(3-吡啶基甲基)-8H-茚并〔1,2-d〕噻唑300mg溶于二甲苯5ml中,加入苄基溴148ml,加热回流3天。蒸去溶剂,将所得残渣溶于甲醇4ml、水1ml中,加入硼氢化钠60mg,室温搅拌30分钟。蒸去溶剂,在所得残渣中加入乙酸乙酯和1N盐酸,分取水层,用碳酸氢钠中和后,用氯仿萃取。分取的氯仿层用无水硫酸钠干燥。蒸去溶剂,所得残渣进行硅胶柱层析,从己烷-乙酸乙酯(3∶1)洗脱部分得到107mg 2-〔(1-苄基-1,2,3,6-四氢-5-吡啶基)甲基〕-8H-茚并〔1,2-d〕噻唑,为油状物。
质谱(m/z):358(M+)
核磁共振谱(CDCl3,TMS内标)
δ:2.23(2H,br),2.54(2H,t),3.01-3.03(2H,m),3.58(2H,s),3.74(2H,s),3.80(2H,s),5.71(1H,m),7.21-7.80(9H,m)
2-〔(1-甲基-1,2,3,6-四氢-4-吡啶基)甲基〕-8-茚并〔1,2-d〕噻唑富马酸盐
原料化合物:
2-(4-吡啶基甲基)-8H-茚并〔1,2-d〕噻唑,碘甲烷
熔点:162-164℃甲醇-乙醚
元素分析值(以C17H18N2S·C4H4O4·0.4H2O计)
C(%) H(%) N(%) S(%)
理论值 62.17 5.66 6.91 7.90
实验值 62.09 5.61 6.90 8.20
质谱(m/z):283(M++1)
核磁共振谱(DMSO-d6,TMS内标)
δ:2.20(2H,br),2.42(3H,s),2.73(2H,t),3.16(2H,br),3.80(2H,s),3.91(2H,s),5.64(1H,s),6.57(1H,s),7.25(1H,t),7.36(1H,t),7.56(1H,d),7.63(1H,d)实施例16
将2-溴-1-二氢茚酮630mg溶于异丙醇10ml中,在溶液中加入3-二甲氨基硫代丙酰胺盐酸盐555mg,加热回流4小时。滤取生成的沉淀,将其分配于氯仿和饱和碳酸氢钠水溶液。分取有机层,用水、饱和氯化钠水溶液相继洗涤后,用无水硫酸钠干燥,蒸去溶剂。将所得残渣溶于甲醇,在溶液中加入富马酸,滤取生成的结晶,用甲醇、乙醚相继洗涤后,用甲醇重结晶,得到2-(2-二甲氨基乙基)-8H-茚并〔1,2-d〕噻唑富马酸盐226mg。
熔点:142-144℃甲醇
质谱(m/z):245(M++1)
核磁共振谱(DMSO-d6,TMS内标)
δ:2.35(6H,s),2.86(2H,t),3.23(2H,t),3.90(2H,s),6.59(2H,s),7.25(1H,t),7.36(1H,t),7.55(1H,d),7.62(1H,d)
2-(3-二甲氨基丙基)-8H-茚并〔1,2-d〕噻唑1.5富马酸盐
原料化合物:
2-溴-1-二氢茚酮,4-二甲氨基硫代丁酰胺盐酸盐
熔点:123-125℃甲醇
元素分析值(以C15H18N2S·1.5C4H4O4计)
C(%) H(%) N(%) S(%)
理论值 57.84 5.64 6.42 7.35
实验值 57.71 5.55 6.41 7.59
质谱(m/z):258(M+)
核磁共振谱(DMSO-d6,TMS内标)
δ:2.10(2H,m),2.59(6H,s),2.91(2H,t),3.13(2H,t),3.91(2H,s),6.56(2H,s),7.14(1H,t),7.28(1H,t),7.34(1H,d),7.46(1H,d)实施例18
2-(2-二乙氨基乙基)-8H-茚并〔1,2-d〕噻唑富马酸盐
原料化合物:
2-溴-1-二氢茚酮,3-二乙氨基硫代丙酰胺盐酸盐
熔点:115-117℃甲醇
元素分析值(以C16H20N2S·C4H4O4计)
C(%) H(%) N(%) S(%)
理论值 61.83 6.23 7.21 8.25
实验值 61.57 6.22 7.14 8.35
质谱(m/z):272(M+)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.08(6H,t),2.81(4H,q),3.12(2H,t),3.33(2H,t),3.90(2H,s),6.57(2H,s),7.26(1H,t),7.37(1H,t),7.55(1H,d),7.63(1H,d)实施例19
2-〔3-(1-吡啶基丙基〕-8H-茚并〔1,2-d〕噻唑富马酸盐
原料化合物:
2-溴-1-二氢茚酮,4-(1-吡啶基)硫代丁酰胺盐酸盐
熔点:165-167℃甲醇
元素分析值(以C17H20N2S·C4H4O4计)
C(%) H(%) N(%) S(%)
理论值 62.98 6.04 6.99 8.01
实验值 62.88 6.08 7.04 8.16
质谱(m/z):284(M+)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.81-1.84(6H,m),2.90-2.95(8H,m),3.13(2H,t),3.90(2H,s),6.51(2H,s),7.26(1H,t),7.37(1H,t),7.56(1H,d),7.63(1H,d)实施例20
2-(3-吗啉基丙基)-8H-茚并〔1,2-d〕噻唑富马酸盐
原料化合物:
2-溴-1-二氢茚酮,4-吗啉基硫代丁酰胺盐酸盐
熔点:163-166℃甲醇
元素分析值(以C17H20N2OS·C4H4O4计)
C(%) H(%) N(%) S(%)
理论值 58.53 5.99 6.50 7.44
实验值 58.66 5.53 6.04 7.38
质谱(m/z):300(M+)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.92-1.99(2H,m),2.42-2,49(6H,m),3.10(2H,t),3.59(4H,t),3.90(2H,s),6.62(2H,s),7.25(1H,t),7.36(1H,t),7.56(1H,d),7.62(1H,d)实施例21
2-〔(1-苄基-3-哌啶基)甲基〕-8H-茚并〔1,2-d〕噻唑二盐酸盐一水合物
原料化合物:
2-溴-1-二氢茚酮,(1-苄基-3-哌啶基)硫代惭酰胺盐酸盐
熔点:139℃(分解)乙酸乙酯
元素分析值(以C23H24N2S·2HCl·H2O计)
C(%) H(%) N(%) S(%) Cl(%)
理论值 61.19 6.25 6.21 7.10 15.71
实验值 61.19 5.96 6.19 7.10 16.03
质谱(m/z):361(M++1)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.18-1.25(1H,m),1,78-1.96(3H,m),2.50-2.60(1H,m),2.72-2.82(2H,m),3.00-3.08(2H,m),3.27(1H,d),3.42(1H,d),3,90(2H,s),4.26(2H,d),7.25-7.29(1H,m),7.37-7.44(4H,m),7.56-7.66(4H,m),7.77(1H,br),11.27(1H,br)实施例22
2-(1-苄基-3-吡咯烷基)-8H-茚并〔1,2-d〕噻唑盐酸盐
原料化合物:
(1-苄基-3-吡咯烷基)硫代甲酰胺盐酸盐,2-溴-1-二氢茚酮
熔点:179-180℃甲醇
元素分析值(以C21H20N2S·HCl·0.45H2O)
C(%) H(%) N(%) S(%) CL(%)
理论值 66.90 5.85 7.43 8.50 9.40
实验值 66.61 5.88 7.41 8.62 9.6
质谱(m/z):322(M+)
核磁共振谱(DMSO-d6,TMS内标)
δ:2.21-2.43(1H,m),2,51-2,67(1H,m),3.28-3.32(1H,m),3.47-3.54(2H,m),3.67-3.85(1H,m),3.94(2H,d),4.01-4.33(1H,m),4.49(2H,dd),7.25-7,30(1H,m),7.35-7.41(1H,m),7.46-7.48(3H,m),7.56-7.69(4H,m)实施例23
2-〔(1-苄基-2-吡咯烷基)甲基〕-8H-茚并〔1,2-d〕噻唑
原料化合物:
〔(1-苄基-2-吡咯烷基)甲基〕-8H-茚并盐酸盐,2-溴-1-二氢茚酮
质谱(m/z):347(M++1)
核磁共振谱(CDCl3,TMS内标)
2-〔(1-苄基-3-吡咯烷基)甲基〕-8H-茚并〔1,2-d〕噻唑二盐酸盐二水合物
原料化合物:
(1-苄基-3-吡咯烷基)硫代甲酰胺盐酸盐,2-溴-1-二氢茚酮
熔点:118-121℃乙酸乙酯-甲醇
元素分析值(以C22H22N2S·2HCl·2.2H2O计)
C(%) H(%) N(%) S(%) Cl(%)
理论值 57.56 6.24 6.10 6.99 15.45
实验值 57.62 5.82 6.16 6.99 15.44
质谱(m/z):346(M+)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.72-1.93(1H,m),2.10-2.29(1H,m),2.78-3.57(7H,m),3.91(2H,s),4.35-4.38(2H,m),7.26(1H,t),7.37(1H,t),7.53-7.63(7H,m)实施例25
2-〔〔(S)-1-〔(R)-1-苯乙基〕-3-吡咯烷基〕甲基〕-8H-茚并〔1,2-d〕噻唑二盐酸盐
原料化合物:
〔(S)-1-〔(R)-1-苯乙基〕-3-吡咯烷〕硫代乙甲酰胺盐酸盐,2-溴-1-二氢茚酮
熔点:132-135℃乙醇-乙酸乙酯
〔α〕D 20+18.21°(c=1.01,甲醇)
质谱(m/z):361(M++1)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.61-1.67(3H,m),1.75-2.30(2H,m),2.80-3.06(3H,m),3.14-3.36(3H,m),3.78-4.05(3H,m),4.47-4.52(1H,m),7.23-7.29(1H,m),7.34-7.46(4H,m),7.53-7.74(4H,m),9.14(1H,br),11.66(1H,br)实施例26
2-〔〔(R)-1-〔(R)-1-苯乙基〕-3-吡咯烷基〕甲基〕-8H-茚并〔1,2-d〕噻唑二盐酸盐
原料化合物:
〔(R)-1-〔(R)-1-苯乙基〕-3-吡咯烷〕硫代乙酰胺盐酸盐,2-溴-1-二氢茚酮
熔点:139-142℃乙醇-乙酸乙酯
〔α〕D 20+11.21°(c=1.07,甲醇)
质谱(m/z):361(M++1)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.64-1.92(4H,m),2.13-2.24(1H,m),2.75-3.08(3H,m),3.15-3.78(4H,m),3.86-3.92(2H,m),4.50-4.58(1H,m),7.23-7.73(9H,m),10.13(1H,br),11.50(1H,r)实施例27
2-〔2-(1-甲基-2-吡咯烷基)乙基〕-8H-茚并〔1,2-d〕噻唑富马酸盐
原料化合物:
2-溴-1-二氢茚酮,3-(1-甲基-2-吡咯烷)硫代丙酰胺盐酸盐
熔点:138-139℃丙酮
元素分析值(以C17H20N2S·C4H4O4·0.4H2O计)
C(%) H(%) N(%) S(%)
理论值 61.87 6.13 6.87 7.87
实验值 61.84 6.08 6.82 7.84
质谱(m/z):284(M+)
核磁共振谱(DMSO-d6TMS内标)
δ:1.62-1.71(1H,m),1.81-1.89(2H,m),1.91-1.98(1H,m),2.11-2.19(1H,m),2.30-2.36(1H,m),2.53(3H,s),2.65-2.69(1H,m),2.87(1H,br),3.09-3.24(2H,m),3.34-3.37(1H,m),3.93(2H,s),6.57(2H,s),7.28(1H,dd),7.39(1H,t),7.58(1H,d),7.66(1H,d)实施例28
外-3-(8H-茚并〔1,2-d〕噻唑-2基)-8-甲基-氮杂二环〔3.2.1〕辛烷富马酸盐
原料化合物:
外-8-甲基-8-氮杂二环〔3.2.1〕辛烷-3-硫代甲酰胺盐酸盐
熔点:179-180℃乙腈
质谱(m/z):296(M+)
核磁共振谱(DMSO-d6,TMS内标)
δ:2.1-2.4(8H,m),2.70(3H,s),3.71(1H,五重峰),3.93(2H,s),3.97(2H,s),6.64(2H,s),7.27(1H,t),7.37(1H,t),7.57(1H,d),7.61(1H,d)实施例29
外-3-〔(8H-茚并〔1,2-d〕噻唑-2-基)甲基〕-8-甲基-8-氮杂二环〔3.2.1〕辛烷富马酸盐
原料化合物:
外-8-甲基-8-氮杂二环〔3.2.1〕辛烷-3-硫代乙酰胺盐酸盐
熔点:211-213℃(分解)乙腈-甲醇元素分析值(以C19H22N2S·C4H4O4计)
C(%) H(%) N(%) S(%)
理论值 64.77 6.14 6.57 7.52
实验值 64.82 6.09 6.53 7.69
质谱(m/z):310(M+)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.61(2H,d),1.98(2H,dd),2.18(2H,m),2.23(2H,m),2.31(1H,m),2.45(3H,s),3.29(2H,d),3.56(2H,s),3.91(2H,s),6.48(2H,s),7.26(1H,t),7.36(1H,t),7.56(1H,d),7.64(1H,d)实施例30
4-(8H-茚并〔1,2-d〕噻唑-2-基)-1-氮杂二环〔2.2.1〕庚烷富马酸盐
原料化合物:
2-溴-1-二氢茚酮,1-氮杂二环〔2.2.1〕庚烷-4-硫代甲酰胺盐酸盐
熔点:160-162℃乙醇
质谱(m/z):269(M+)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.94(2H,m),2.27(2H,m),2.90-3.10(4H,m)3.27(2H,m),3.94(2H,s),6.59(2H,s),7.27(1H,t,J=7.5Hz),7.37(1H,t,J=7.5Hz),7.58(1H,d,J=7.5Hz),7.65(1H,d,J=7.5Hz)实施例31
(4R*,5R*)-4-(8H-茚并〔1,2-d〕噻唑-2-基)-1-氮杂二环〔3.3.1〕壬烷富马酸盐
原料化合物:
2-溴-1-二氯茚酮,(4R*,5R*)-1-氮杂二环〔3.3.1〕壬烷-4-硫代甲酰胺
熔点:195-196℃乙醇
元素分析值(以C18H20N2S·C4H4O4·0.25H2O计)
C(%) H(%) N(%) S(%)
理论值 63.37 5.92 6.72 7.69
实验值 63.54 5.89 6.80 7.56
质谱(m/z):296(M+)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.40-1.80(3H,m),2.00-2.40(2H,m),2.55-2.70(1H,m),3.21(3H,m),3.30-3.45(2H,m),3.77(1H,m),3.94(2H,s),6.51(2H,s),7.26(1H,t,J=7.0Hz),7.37(1H,t,J=7.0Hz),7.57(1H,d,J=7.0Hz),7.64(1H,d,J=7.0Hz)实施例32
5-氟-2-(1-甲基-3-吡咯烷基)-8H-茚并〔1,2-d〕噻唑二盐酸盐
原料化合物:
(1-甲基-3-吡咯烷基)硫代甲酰胺盐酸盐,2-溴-6-氟-1-二氢茚酮
熔点:178-182℃甲醇-乙酸乙酯
元素分析值(以C15H15N2SF·2HCl·0.5H2O计)
C(%)H(%) N(%)S(%) Cl(%)F(%)
理论值 50.57 5.09 7.86 9.00 19.90 5.33
实验值 50.92 5.01 7.90 8.99 19.73 5.40
质谱(m/z):275(M++1)
核磁共振谱(DMSO-d6,TMS内标)
δ:2.21-2.43(1H,m),2.52-2.68(1H,m),2.88-2.92(3H,m),3.18-3.31(1H,m),3.37-3.74(2H,m),3.79-4.02(3H,m),4.08-4.36(1H,m),7.06-7.12(1H,m),7.39-7.44(1H,m),7.56-7.61(1H,m),10.51(1H,br),11.80(1H,br)实施例33
2-(1-甲基-3-吡咯烷基)-4,5-二氢萘并〔1,2-d〕噻唑二盐酸盐
原料化合物:
(1-甲基-3-吡咯烷)硫代甲酰胺盐酸盐,2-溴-1-四氢萘酮
熔点:182-183℃甲醇-乙酸乙酯
元素分析值(以C16H18N2S·2.1HCl计)
C(%) H(%) N(%) S(%) Cl(%)
理论值 55.39 5.84 8.07 9.29 21.46
实验值 55.31 5.81 8.13 9.34 21.12
质谱(m/z):271(M++1)
核磁共振谱(DMSO-d6,TMS内标)
δ:2.16-2.36(1H,m),2.45-2.63(1H,m),2.86-2.91(3H,m),3.01(s,4H),3.15-3.29(1H,m),3.34-3.71(2H,m),3.77-4.24(2H,m),7.20-7.31(3H,m),7.78(7.81(1H,m),11.08(1H,br),11.71(1H,br)实施例34
6-甲氧基-2-(1-甲基-3-吡咯烷基)-4,5-二氢萘并〔1,2-d〕噻唑二盐酸盐
原料化合物:
(1-甲基-3-吡咯烷)硫代甲酰胺盐酸盐,2-溴-5-甲氧基-1-四氢萘酮
熔点:118-120℃甲醇-乙酸乙酯
质谱(m/z):301(M++1)
核磁共振谱(DMSO-d6,TMS内标)
δ:2.14-2.36(1H,m),2.44-2.63(1H,m),2.83-3.02(7H,m),3.14-3.28(1H,m),3.33-3.73(2H,m),3.77-4.24(5H,m),6.93-6.96(1H,m),7.24-7.29(1H,m),7.44-7.46(1H,m),9.03(1H,br),11.67(1H,br)实施例35
5-甲基-2-(1-甲基-3-吡咯烷基)-4,5-二氢萘并〔1,2-d〕噻唑二盐酸盐
原料化合物:
(1-甲基-3-吡咯烷)硫代甲酰胺盐酸盐,2-溴-4-甲基-1-四氢萘酮
熔点:122-124℃甲醇-乙酸乙酯
元素分析值(以C17H20N2S·2.1HCl计)
C(%) H(%) N(%) S(%) Cl(%)
理论值 56.56 6.17 7.76 8.88 20.62
实验值 56.54 6.21 7.78 8.80 20.22
质谱(m/z):285(M++1)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.22(3H,d,J=5.4Hz),2.15-2.38(1H,m),2.45-2.65(1H,m),2.82-2.92(4H,m),3.12-3.28(3H,m),3.34-3.73(2H,m),3.77-4.26(2H,m),7.24-7.32(3H,m),7.82(1H,d,J=7.3Hz),10.37(1H,br),11.67(1H,br)实施例36
1-苄基-2-〔〔4-(2-噻吩基)-2-噻唑基〕甲基〕哌啶
原料化合物:
2-(溴乙基)噻吩,(1-苄基-2-哌啶)硫代乙酰胺盐酸盐
质谱(m/z):354(M+)
核磁共振谱(CDCl3,TMS内标)
δ:1.20-1.95(6H,m),2.00-2.40(1H,m),2.65-3.10(2H,m),3.35(2H,dd,J=5,7Hz),3.46(1H,d,J=13Hz),4.04(1H,d,J=13Hz),7.03(1H,dd,J=4.5Hz),7.18-7.55(7H,m),7.23(1H,s)实施例37
1-苄基-2-〔2-〔4-(2-噻吩基)-2-噻唑基〕乙基〕哌啶
原料化合物:
2-(溴乙酰基)噻吩,3-(1-苄基-2-哌啶)硫代丙酰胺盐酸盐
核磁共振谱(CDCl3,TMS内标)
δ:1.3-1.8(6H,m),2.0-2.3(3H,m),2.3-2.6(1H,m),2.7-2.9(1H,m),3.0-3.2(2H,m),3.31(2H,d,J=14Hz),4.02(1H,d,J=14Hz),7.0-7.4(9H,m)实施例38
2-(1-甲基-3-吡咯烷基)-4-(2-噻唑基)噻唑草酸盐
原料化合物:2-(溴乙酰基)噻唑、(1-甲基-3-吡咯烷)硫代甲酰胺盐酸盐
δ:2.21-2.31(1H,m),2.50-2.61(1H,m),2.84(3H,s),3.37(2H,t),3.48(1H,dd),3.74(1H,dd),4.04-4.16(1H,m),7.79(1H,d),7.92(1H,d),8.21(1H,s)实施例39
2-(1-甲基-3-吡咯烷基)-4-(2-噻吩基)噻唑草酸盐
原料化合物:2-(溴乙酰基)噻吩、(1-甲基-3-吡咯烷)硫代甲酰胺盐酸盐
熔点:144℃(丙酮)
元素分析(C12H14N2S2·C2H2O4)
C(%) H(%) N(%) S(%)
理论值 49.40 4.74 8.23 18.84
实验值 49.35 4.75 8.15 18.77
质谱(m/z):251(M+1)
核磁共振谱(DMSO-d6,TMS内标)
δ:2.19-2.28(1H,m),2.49-2.58(1H,m),2.85(3H,s),3.36(2H,t),3.45(1H,dd),3.73(1H,dd),4.03-4.11(1H,m),7.12(1H,dd),7.53(1H,dd),7.57(1H,dd),7.91(1H,s)实施例40
2-(1-甲基-3-吡咯烷基)-4-(3-噻吩基)噻唑草酸盐
原料化合物:3-(溴乙酰基)噻吩、(1-甲基-3-吡咯烷)硫代甲酰胺盐酸盐
熔点:171℃(丙酮)
元素分析(C12H14N2S2·C2H2O4)
C(%) H(%) N(%) S(%)
理论值 49.40 4.74 8.23 18.84
实验值 49.22 4.69 8.24 18.58
质谱(m/z):251(M++1)
核磁共振谱(DMSO-d6,TMS内标)
δ:2.19-2.28(1H,m),2.50-2.58(1H,m),2.85(3H,s),3.36(2H,t),3.49(1H,dd),3.71(1H,dd),4.04-4.12(1H,m),7.59-7.63(2H,m),7.89-7.92(2H,m)实施例41
4-(2-呋喃基)-(1-甲基-3-吡咯烷基)噻唑草酸盐
原料化合物:2-(溴乙酰基)呋喃、(1-甲基-3-吡咯烷)硫代甲酰胺盐酸盐
熔点:144℃(丙酮)
元素分析(C12H14N2OS·C2H2O4)
C(%) H(%) N(%) S(%)
理论值 51.84 4.97 8.64 9.89
实验值 51.60 4.99 8.62 9.84
质谱(m/z):235(M++1)
核磁共振谱(DMSO-d6,TMS内标)
δ:2.19-2.28(1H,m),2.50-2.58(1H,m),2.83(3H,s),3.35(2H,t),3.45(1H,dd),3.71(1H,dd),4.03-4.12(1H,m),6.60(1H,dd),6.81(1H,d),7.75(1H,d),7.77(1H,s)实施例42
2-(1-甲基-3-吡咯烷基)-4-(3-甲基-2-噻吩基)噻唑富马酸盐
原料化合物:(1-甲基-3-吡咯烷)硫代甲酰胺盐酸盐、2-溴乙酰基-3-甲基噻唑
熔点:127-129℃(乙腈/甲醇)
元素分析(C13H16N2S·C4H4O4)
C(%) H(%) N(%) S(%)
理论值 53.66 5.30 7.36 16.86
实验值 53.61 5.23 7.31 16.88
质谱(m/z):264(M+)
核磁共振谱(DMSO-d6,TMS内标)
δ:2.03-2.11(1H,m),2.37-2.46(4H,m),2.49(3H,s),2.78-2.84(1H,m),2.89-2.97(2H,m),3.15-3.19(1H,m),3.84-3.9l(1H,m),6.57(2H,s),6.96(1H,d),7.40(1H,d),7.59(1H,s)实施例43
2-(1-甲基-3-吡咯烷基)-4,5-二氢噻吩并〔3,2-e〕苯并噻唑富马酸盐
原料化合物:(1-甲基-3-吡咯烷)硫代甲酰胺盐酸盐、5-溴-4,5,6,7-四氢苯并〔b〕噻吩-4-酮
熔点:165-169℃(甲醇)
元素分析(C14H16N2S2·C4H4O4)
C(%) H(%) N(%) S(%)
理论值 55.08 5.14 7.14 16.34
实验值 55.10 5.08 7.08 16.38
质谱(m/z):276(M+1)
核磁共振谱(DMSO-d6,TMS内标)
δ:2.00-2.08(1H,m),2.33-2.42(1H,m),2.45(3H,s),2.75(1H,q),2.83-2.89(2H,m),3.08-3.11(5H,m),3.78-3.85(1H,m),6.58(2H,s),7.27(1H,d),7.38(1H,d)实施例44
2-(1-甲基-3-吡咯烷基)-4,5-二氢噻唑并〔5,4-h〕喹啉1.5盐酸盐1水合物
熔点:176-179℃(分解)(乙酸乙酯/甲醇)
元素分析(C15H17N3S·1.55HCl·H2O)
C(%) H(%) N(%) S(%) Cl(%)
理论值 52.08 5.99 12.15 9.27 15.89
实验值 51.82 5.91 12.11 9.06 15.93
质谱(m/z):271(M+)
核磁共振谱(DMSO-d6,TMS内标)
δ:2.13-2.35(1H,m),2.55-2.70(1H,m),2.93(3H,s),3.17(2H,s),3.22-4.28(7H,m),7.47-7.61(1H,m),8.00-8.18(1H,m),8.49-5.54(1H,m)实施例45
2-(1-甲基-3-吡咯烷基)-4,5-二氢呋喃并〔2,3-e〕苯并噻唑草酸盐
原料化合物:6-溴-7-氧代-4,5,6,7-四氢苯并呋喃、(1-甲基-3-吡咯烷)硫代甲酰胺盐酸盐
熔点:165-168℃(乙酸乙酯/甲醇)
质谱(m/z):260(M+)
核磁共振谱(DMSO-d6,TMS内标)
δ:2.19-2.22(1H,m),2.50(1H,m),2.80(3H,s),2.83(2H,t),3.07(2H,t),3.31(2H,m),3.42(1H,m),3.61(1H,m),4.00(1H,m),6.52(1H,d),7.59(1H,d)实施例46
4-苯基-2-(3-哌啶基)噻唑富马酸盐
原料化合物:2-溴乙酰苯、3-哌啶硫代甲酰胺
熔点:145-148℃(乙醇/乙腈)
元素分析(C14H16N2S·C4H4O4)
C(%) H(%) N(%) S(%)
理论值 59.98 5.59 7.77 8.90
实验值 59.63 5.54 7.70 8.98
质谱(m/z):244(M+)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.70-1.85(3H,m),2.15-2.25(1H,m),2.75-2.85(1H,m),3.02(1H,dd),3.18(1H,d),3.40-3.45(1H,m),3.53(1H,d),6.48(2H,s),7.34(1H,dd),7.44(2H,dd),7.96(2H,d),8.04(1H,s)实施例47
将4-哌啶基丁腈1.11g溶解于4N盐酸-乙酸乙酯溶液10ml中,往该溶液中加入二硫代磷酸O,O-二乙酯1.22ml,室温下搅拌20小时。滤取生成的沉淀,用乙酸乙酯和乙醚依次洗涤,得到4-哌啶子基丁烷硫代甲酰胺盐酸盐1.02g。接着加入2-溴-2,3-二氢-1-茚酮0.95g,并溶解于异丙醇10ml中,加热回流7小时。滤取生成的沉淀,将其在氯仿和饱和碳酸氢钠水溶液中分配。分出有机层,用水和饱和氯化钠水溶液依次洗涤后,用无水硫酸钠干燥,蒸去溶剂。将所得残渣溶解于甲醇中,再加入富马酸,滤取生成的结晶,用甲醇和乙酸乙酯依次洗涤后,用甲醇重结晶,得到2-(3-哌啶基丙基)8H-茚并〔1,2-d〕噻唑·1.5富马酸盐510mg。
熔点:133-135℃(甲醇)
元素分析(C18H22N2S·1.5C4H4O4)
C(%) H(%) N(%) S(%)
理论值 59.86 6.07 5.82 6.66
实验值 59.86 5.80 6.08 6.68
质谱(m/z):398(M+)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.45-1.47(2H,m),1.60-1.66(4H,m),2.04-2.12(2H,m),2.77-2.81(6H,m),3.12(2H,t),3.91(2H,s),6.57(1H,s),7.25(1H,t),7.36(1H,t),7.56(1H,d),7.63(1H,d)
按与实施例47相同的方法,得到了下述实施例48-51的化合物。实施例48
5-〔(8H-茚并〔1,2-d〕噻唑-2-基)甲基〕-1-氮杂二环〔3.3.0〕辛烷富马酸盐
原料化合物:1-氮杂二环〔3.3.0〕辛烷-5-乙腈
熔点:201-202℃(甲醇)
元素分析(C18H20N2S·C4H4O4)
C(%) H(%) N(%) S(%)
理论值 64.06 5.86 6.79 7.77
实验值 63.79 5.89 6.74 7.79
质谱(m/z):297(M++1)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.79-1.85(2H,m),2.00-2.03(4H,m),2.31-2.36(2H,m),2.87-2.92(2H,m),3.52(2H,s),3.57-3.62(2H.m),3.84(2H,s),6.69(2H,s),7.24(1H,t),7.35(1H,t),7.51(1H,d),7.69(1H,d)实施例49
2-〔3-(1-氮杂二环〔2.2.2〕辛基〕-8H-茚并〔1,2-d〕噻唑富马酸盐
原料化合物:3-氰基-(1-氮杂二环〔2.2.2〕辛烷)
熔点:199-202℃(甲醇)
元素分析(C17H18N2S·C4H4O4)
C(%) H(%) N(%) S(%)
理论值 63.30 5.56 7.03 8.05
实验值 63.50 5.67 6.95 7.95
质谱(m/z):283(M++1)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.62-1.99(4H,m),2.29-2.30(1H,m),3.02-3.17(4H,m),3.53-3.75(3H,m),3.94(2H,s),6.52(2H,s),7.27(1H,t),7.35(1H,t),7.51(1H,d),7.69(1H,d)实施例50
2-(1-甲基-4-哌啶基)-8H-茚并〔1,2-d〕噻唑富马酸盐
原料化合物:(1-甲基-4-哌啶)腈
熔点:189-191℃(乙腈/甲醇)
元素分析(C16H18N2S·C4H4O4)
C(%) H(%) N(%) S(%)
理论值 61.58 5.79 7.18 8.22
实验值 61.68 5.75 7.11 8.41
质谱(m/z):270(M+)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.96(2H,q),2.20(2H,d),2.52(3H,s),2.64(2H,t),3.19-3.27(3H,m),3.92(2H,s),6.58(2H,s),7.26(1H,t),7.37(1H,t),757(1H,d),7.64(1H,d)实施例51
2-(1-甲基-哌啶基)-8H-茚并〔1,2-d〕噻唑富马酸盐
原料化合物:(1-甲基-3-哌啶)腈
熔点:170-172℃(乙腈/异丙醇)
元素分析(C16H18N2S·C4H4O4·0.3H2O)
C(%) H(%) N(%) S(%)
理论值 61.30 5.81 7.15 8.18
实验值 61.03 5.72 7.18 7.91
质谱(m/z):270(M+)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.55-1.73(2H,m),1.76-1.81(1H,m),2.07-2.10(1H,m),2.22(1H,t),2.35(1H,s),2.43(1H,t),2.84(1H,d),3.20(1H,d),3.35-3.41(1H,m),3.91(2H,s),6.59(2H,s),7.25(1H,t),7.36(1H,t),7.56(1H,d),7.63(1H,d)实施例52
往2-(1-苄基-3-吡咯烷基)-8H-茚并〔1,2-d〕噻唑0.86g在5ml二氯乙烷中的溶液中加入氯甲酸1-氯乙酯5ml,加热回流2小时。冷却后,蒸去溶剂,往残留物中加入甲醇10ml,再加热回流2小时。反应终止后,加入乙酸乙酯,用1N盐酸提取,提取物用碳酸氢钠中和后,用氯仿提取。用无水硫酸镁干燥后,蒸去溶剂,得到2-(3-吡咯烷基)-8H-茚并〔1,2-d〕噻唑0.18g。将其溶解于甲醇中,加入富马酸使其结晶,再用乙腈/甲醇重结晶,制成富马酸盐。
熔点:185-188℃(乙腈/甲醇)
元素分析(C14H14N2S·C4H4O4·0.1H2O)
C(%) H(%) N(%) S(%)
理论值 60.02 5.09 7.78 8.90
实验值 59.82 5.14 7.72 8.90
质谱(m/z):242(M+)
核磁共振谱(DMSO-d6,TMS内标)
δ:2.11-2.20(1H,m),2.40-2.48(1H,m),3.18-3.25(1H,m),3.29-3.36(2H,m),3.63(1H,dd),3.89-3.99(3H,m),6.47(2H,s),7.27(1H,t),7.37(1H,t),7.57(1H,d),7.65(1H,d)
按与实施例52相同的方法,得到了下述实施例53-60的化合物。实施例53
2-(3-吡咯烷基甲基)-8H-茚并〔1,2-d〕噻唑富马酸盐
原料化合物:2-〔(1-苄基-3-吡咯烷基)甲基〕-8H-茚并〔1,2-d〕噻唑
熔点:183-185℃(乙腈/甲醇)
元素分析(C15H16N2S·C4H4O4·0.3H2O)
C(%) H(%) N(%) S(%)
理论值 60.40 5.50 7.41 8.49
实验值 60.35 5.32 7.58 8.43
质谱(m/z):256(M+)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.63-1.72(1H,d),2.04-2.12(1H,m),2.68-2.76(1H,m),2.91(1H,dd),3.08-3.35(5H,m),3.92(2H,s),6.43(2H,s),7.26(1H,t),7.34(1H,t),7.57(1H,d),7.64(1H,d)实施例54
2-(2-吡咯烷基甲基)-8H-茚并〔1,2-d〕噻唑富马酸盐
原料化合物:2-〔(1-苄基-2-吡咯烷基)甲基〕-8H-茚并〔1,2-d〕噻唑
熔点:148℃(分解)(乙腈)
元素分析(C15H16N2S·C4H4O4·H2O)
C(%) H(%) N(%) S(%)
理论值 58.45 5.68 7.17 8.21
实验值 58.30 5.26 7.01 7.91
质谱(m/z):257(M++1)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.64-1.74(1H,m),1.80-1.97(2H,m),2.04-2.13(1H,m),3.09-3.27(2H,m),3.40-3.59(2H,m),3.85-3.92(3H,m),6.48(2H,s),7.24-7.28(1H,m),7.35-7.39(m,1H),7.57(1H,d,J=7.8Hz),7.66(1H,d,J=7.3Hz)实施例55
(S)-2-(3-吡咯烷基甲基)-8H-茚并〔1,2-d〕噻唑·2盐酸盐
原料化合物:2-〔〔(S)-1-〔(R)-1-苯基乙基〕-3-吡咯烷基〕甲基〕-8H-茚并〔1,2-d〕噻唑
熔点:152℃(分解)(乙醇/乙酸乙酯)
〔α〕D 25+5.95°(c=0.89,甲醇)
元素分析(C15H16N2S·2HCl·H2O)
C(%) H(%) N(%) S(%) Cl(%)
理论值 54.12 5.57 8.42 9.63 21.30
实验值 54.11 5.34 8.37 9.44 21.00
质谱(m/z):257(M++1)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.65-1.75(1H,m),2.06-2.15(1H,m),2.71-2.79(1H,m),2.90-2.98(1H,m),3.10-3.39(5H,m),3.92(2H,s),7.24-7.28(1H,m,7.37(1H,t,J=7.3Hz),7.57(1H,d,J=7.3Hz),7.65(1H,d,J=7.8Hz),8.86(1H,br),9.46(2H.br)
按与实施例61记载的方法同样地对所得化合物进行了分析,结果发现对映体过量为99%。实施例56
(R)-2-(3-吡咯烷基甲基)-8H-茚并〔1,2-d〕噻唑·2盐酸盐
原料化合物:2-〔〔(R)-1-〔(R)-1-苯基乙基〕-3-吡咯烷基〕甲基〕-8H-茚并〔1,2-d〕噻唑
熔点:149℃(分解)(甲醇/乙酸乙酯)
〔α〕D 25-4.71°(c=0.89,甲醇)
元素分析(C15H16N2S·2HCl)
C(%) H(%) N(%) S(%) Cl(%)
理论值 54.71 5.51 8.51 9.74 21.53
实验值 54.40 5.52 8.47 9.68 21.63
质谱(m/z):257(M++1)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.66-1.76(1H,m),2.06-2.15(1H,m),2.72-2.80(1H,m),2.91-2.99(1H,m),3.09-3.19(1H,m),3.21-3.38(4H,m),3.92(1H,s),7.25-7.29(1H,m),7.38(1H,t,J=7.3),7.57(1H,d,J=7.8),7.67(1H,d,J=7.3),9.69(2H,br),11.03(1H,br)
2-(3-吡咯烷基甲基)-8H-茚并〔1,2-d〕噻唑·2盐酸盐
原料化合物:2-〔(1-苄基-3-吡咯烷基)甲基〕-8H-茚并〔1,2-d〕噻唑
熔点:163℃(分解)(甲醇/乙酸乙酯)
元素分析(C15H18N2S·2HCl·0.5H2O)
C(%) H(%) N(%) S(%) Cl(%)
理论值 54.54 6.01 7.95 9.10 20.12
实验值 54.25 5.78 7.88 9.05 20.03
质谱(m/z):271(M++1)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.25-1.34(1H,m),1.63-1.83(3H,m),2.27-2.36(1H,m),2.66-2.79(2H,m),3.02-3.27(4H,m),3.92(2H,s),7.26(1H,dd,J=6.3,7.3Hz),7.37(1H,t,J=7.3Hz),7.50-7.70(3H,m),9.10-9.50(2H,m)实施例58
2-〔(1,2,3,6-四氢-5-吡啶基)甲基〕-8H-茚并〔1,2-d〕噻唑富马酸盐
原料化合物:2-(3-吡啶基甲基)-8H-茚并〔1,2-d〕噻唑
熔点:168℃(甲醇/乙醚)
元素分析(C16H16N2S·C4H4O4·0.1H2O)
C(%) H(%) N(%) S(%)
理论值 62.19 5.27 7.25 8.30
实验值 61.24 5.15 7.11 8049
质谱(m/z):268(M+)
核磁共振谱(DMSO-d6,TMS内标)
δ:2.20(2H,br),2.98(2H,t),3.46(2H,s),3.81(2H,s),3.91(2H,s),5.82(1H,br),6.45(2H,s),7.26(1H,t),7.37(1H,t),7.56(1H,d),7.64(1H,d)实施例59
2-〔〔4-(2-噻吩基)-2-噻唑基〕甲基〕哌啶·0.5富马酸盐
原料化合物:1-苄基-2-〔〔4-(2-噻吩基)-2-噻唑基〕甲基〕哌啶
熔点:181-183℃(甲醇/乙酸乙酯)
元素分析(C13H16N2S2·0.5C4H4O4)
C(%) H(%) N(%) S(%)
理论值 55.87 5.63 8.69 19.89
实验值 55.83 5.61 8.60 19.83
质谱(m/z):264(M+)
核磁共振谱(CDCl3,TMS内标)(游离化合物的形式)
δ:1.00-1.95(6H,m),2.11(1H,s),2.43-2.77(1H,m),2.85-3.25(4H,m),7.01(1H,dd,J=4.5Hz),7.17(1H,s),7.23(1H,dd,J=1,5Hz),7.41(1H,dd,J=1.4Hz)实施例60
2-〔2-〔4-(2-噻吩基)-2-噻唑基〕乙基〕哌啶·0.5富马酸盐
原料化合物:1-苄基-2-〔2-〔4-(2-噻吩基)-2-噻唑基〕乙基〕哌啶
熔点:176-180℃(乙醇)
质谱(m/z):279(M++1)
核磁共振谱(DMSO-d6,TMS内标)(游离化合物形式)
δ:1.3-1.5(3H,m),1.62(1H,m),1.8-2.0(4H,m),2.69(1H,dd,J=9,12Hz),2.84(1H,m),3.1(3H,m),6.41(1H,s),7.10(1H,dd,J=3,5Hz),7.50(1H,dd,J=1.5Hz),7.54(1H,dd,J=1.3Hz),7.80(1H,s)实施例61
往2-(3-吡咯烷基)-8H-茚并〔1,2-d〕噻唑0.78g在甲醇中的溶液中,加入(-)-O,O’-二苯甲酰基酒石酸·1水合物1.09g,再加入水,滤取析出的结晶,用甲醇-水重结晶3次,得到2-(3-吡咯烷基)-8H-茚并〔1,2-d〕噻唑(-)-二苯甲酰基酒石酸·1水合物0.45g。通过X线衍射,确定该盐为S型。
然后,往该盐中加入饱和碳酸氢钠,用氯仿提取,再用无水硫酸镁干燥。蒸去溶剂,将所得残渣溶解于甲醇中,加入富马酸进行结晶后,用甲醇-乙腈重结晶,得到(S)-2-(3-吡咯烷基)-8H-茚并〔1,2-d〕噻唑富马酸盐。用Daicel化学工业公司生产的CHIRALCEL OD进行高效液相色谱分析(洗脱剂:乙醇/己烷/二乙胺),结果表明对映体过量为99%。
熔点:190-191℃(乙腈/甲醇)
元素分析(C14H14N2S·C4H4O4)
C(%) H(%) N(%) S(%)
理论值 60.32 5.06 7.82 8.95
实验值 60.25 5.01 7.63 8.93
质谱(m/z):242(M+)
核磁共振谱(DMSO-d6,TMS内标)
δ:2.12-2.19(1H,m),2.38-2.47(1H,m),3.17-3.23(1H,m),3.27-3.34(2H,m),3.61(1H,dd),3.90-3.97(3H,m),6.47(2H,s),7.27(1H,t),7.37(1H,t),7.57(1H,d),7.64(1H,d)实施例62
将实施例61的结晶后的母液用碳酸钙中和后,接着用氯仿提取,用无水硫酸镁干燥。蒸去溶剂,往所得残渣(0.52g)在甲醇中的溶液中加入(+)-O,O’-二苯甲酰基酒石酸·1水合物0.727g,再加入水,滤取析出的结晶,用甲醇-水重结晶4次,得到2-(3-吡咯烷基)-8H-茚并〔1,2-d〕噻唑(+)-二苯甲酰基酒石酸·1水合物0.43g。通过X线衍射,确定该盐为R型。
然后,按与实施例61同样的方法处理,得到(R)-2-(3-吡咯烷基)-8H-茚并〔1,2-d〕噻唑富马酸盐。按与实施例61同样的方法,确认该盐的对映体过量为99%。熔点:191-192℃(乙腈/甲醇)元素分析(C14H14N2S·C4H4O4)
C(%) H(%) N(%) S(%)
理论值 60.32 5.06 7.82 8.95
实验值 60.14 4.93 7.85 8.76
质谱(m/z):242(M+)
核磁共振谱(DMSO-d6,TMS内标)
δ:2.10-2.17(1H,m),2.37-2.45(1H,m),3.14-3.20(1H,m),3.24-3.30(2H,m),3.57(1H,dd),3.87-3.93(3H,m),6.47(2H,s),7.27(1H,t),7.37(1H,t),7.57(1H,d),7.64(1H,d)实施例63
将(5S)-1-氮杂二环〔3.3.0〕辛烷-3-腈的非对映异构体混合物5.10g溶解于4N盐酸-乙酸乙酯100ml中,加入二硫代磷酸O,O-二乙酯7g,室温下搅拌16小时。蒸去溶剂,用乙酸乙酯洗涤残渣,减压下干燥,得到(5S)-1-氮杂二环〔3.3.0〕辛烷-3-硫代甲酰胺。将该产物溶解于异丙醇150ml中,加入2-溴-1-茚酮6.3g、碳酸钙3.7g,加热回流5小时。冷却后,滤去不溶物,蒸去溶剂。将残渣用乙酸乙酯和1N盐酸进行分配,分出水层,用碳酸氢钠中和后,再用氯仿提取。用无水硫酸钠干燥分出的氯仿层,蒸去溶剂,将所得残渣用中压制备性层析柱进行色谱分离,由氯仿-甲醇-氨水(200∶10∶1)洗脱部位得到3-(8H-茚并〔1,2-d〕噻唑-2-基)-1-氮杂二环〔3.3.0〕辛烷的(3R,5S)型化合物(实施例63A)0.32g和(3S,5S)型化合物(实施例63B)0.18g。
将(3R,5S)型化合物(实施例63A)溶解于甲醇中,加入富马酸,溶解后蒸去溶剂,用丙酮结晶,制成富马酸盐。(3S,5S)型化合物(实施例63B)系用石油醚结晶。
按与实施例61中所述的相同方法进行分析,确认(3R,5S)型化合物的对映体过量为96%。
进行同样的分析,确认(3S,5S)型化合物的对映体过量为99%。实施例63A
熔点:155-156℃(丙酮)
〔α〕D 25-8.00(c=0.50,甲醇)
元素分析(C17H18N2S·C4H4O4V·H2O)
C(%) H(%) N(%) S(%)
理论值 60.56 5.81 6.73 7.70
实验值 60.63 5.74 6.88 7.65
质谱(m/z):283(M++1)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.81-2.15(6H,m),2.66-2.73(1H,m),3.11-3.29(3H,m),3.93(2H,s),3.96-4.05(1H,m),4.13-4.20(1H,m),6.52(2H,s),7.27(1H,dt),7.38(1H,t),7.57(1H,d),7.64(1H,d)实施例63B
熔点:79-81℃(石油醚)
〔α〕D 25-8.39(c=0.50,氯仿)
元素分析(C17H18N2S·0.1H2O)
C(%) H(%) N(%) S(%)
理论值 71.84 6.45 9.86 11.28
实验值 71.94 6.64 9.81 10.90
质谱(m/z):282(M+)
核磁共振谱(CDCl3,TMS内标)
δ:1.42-1.51(1H,m),1.73-1.92(2H,m),2.05-2.15(2H,m),2.32-2.39(1H,m),2.59-2.64(1H,m),3.16-3.22(3H,m),3.66-3.88(4H,m),7.28(1H,dt),7.36(1H,t),7.48(1H,d),7.76(1H,d)
(3S,5S)-3-(8H-茚并〔1,2-d〕噻唑-2-基)-1-氮杂二环〔3.3.0〕辛烷·富马酸盐
原料化合物:(5R)-1-氮杂二环〔3.3.0〕辛烷-3-腈、2-溴-1-茚酮。
熔点:157-158℃(丙酮)
〔α〕D 25+6.79(c=0.50,甲醇)
元素分析(C17H18N2S·C4H4O4·0.5H2O)
C(%) H(%) N(%) S(%)
理论值 61.90 5.69 6.87 7.87
实验值 62.07 5.52 6.71 7.72
质谱(m/z):283(M+)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.80-1.84(1H,m),1.89-2.12(5H,m),2.65-2.70(1H,m),3.08-3.24(3H,m),3.91-4.01(1H,m),4.10(1H,br),6.52(2H,s),7.26(1H,dd),7.37(1H,t),7.57(1H,d),7.64(1H,d)
(3R,5R)-3-(8H-茚并〔1,2-d〕噻唑-2-基)-1-氮杂二环〔3.3.0〕辛烷
原料化合物:(5R)-1-氮杂二环〔3.3.0〕辛烷-3-腈、2-溴-1-茚酮
熔点:80-81℃(石油醚)
〔α〕D 25+8.00(c=0.50,氯仿)
元素分析(C17H18N2S)
C(%) H(%) N(%) S(%)
理论值 72.30 6.42 9.92 11.35
实验值 72.42 6.47 9.96 11.25
质谱(m/z):282(M+)
核磁共振谱(CDCl3,TMS内标)
δ:1.43-1.50(1H,m),1.73-1.82(1H,m),1.85-1.91(1H,m),2.06-2.14(2H,m),2.32-2.83(1H,m),2.59-2.64(1H,m),3.17-3.26(3H,m),3.75-3.88(2H,m),3.79(2H,s),7.23(1H,dd),7.36(1H,t),7.48(1H,d),7.76(1H,d)
按与实施例61中所述的相同方法进行分析,确认其对映体过量为99%。实施例66
(3R*,5S*)-3-(8H-茚并〔1,2-d〕噻唑-2-基)-1-氮杂二环〔3.3.0〕辛烷·0.5富马酸盐
原料化合物:1-氮杂二环〔3.3.0〕辛烷-3-腈、2-溴-1-茚酮
熔点:123-127℃(丙酮)
质谱(m/z):283(M++1)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.68-2.04(5H,m),2.55-2.62(1H,m),2.88-3.09(3H,m),3.70-4.01(5H,m),6.47(1H,s),7.26(1H,t),7.37(1H,t),7.57(1H,d),7.64(1H,d)实施例67
(3R*,5R*)-3-(8H-茚并〔1,2-d〕噻唑-2-基)-1-氮杂二环〔3.3.0〕辛烷·富马酸盐
原料化合物:1-氮杂二环〔3.3.0〕辛烷-3-腈、2-溴-1-茚酮
熔点:142-144℃(丙酮)
质谱(m/z):283(M++1)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.64-1.76(2H,m),1.93-1.99(1H,m),2.06-2.13(1H,m),2.18-2.24(1H,m),2.31-2.38(1H,m),2.87-2.94(1H,m),3.28-3.42(3H,m),3.92(2H,s),3.98-4.02(1H,m),4.04-4.12(1H,m),6.49(2H,s),7.26(1H,t),7.37(1H,t),7.57(1H,d),7.64(1H,d)实施例68
(3R*,6S*)-3-(8H-茚并〔1,2-d〕噻唑-2-基)-1-氮杂二环〔4.4.0〕癸烷
原料化合物:1-氮杂二环〔4.4.0〕癸烷-3-腈、2-溴-1-茚酮
熔点:110-113℃(己烷)
质谱(m/z):310(M+)
核磁共振谱(CDC3,TMS内标)
δ:1.23-1.36(2H,m),1.44-1.75(6H,m),1.81-1.88(2H,m),2.02-2.11(2H,m),2.46(1H,dd),2.80(1H,d),3.01(1H,d),3.61(1H,s),3.78(2H,d),7.19-7.22(1H,m),7.35(1H,t),7.47(1H,d),7.76(1H,d)实施例69
(3R*,6R*)-3-(8H-茚并〔1,2-d〕噻唑-2-基)-1-氮杂二环〔4.4.0〕癸烷
原料化合物:1-氮杂二环〔4.4.0〕癸烷-3-腈、2-溴-1-茚酮
熔点:117℃(石油醚)
元素分析(C19H22N2S)
C(%) H(%) N(%) S(%)
理论值 73.51 7.14 9.02 10.33
实验值 73.63 7.26 9.05 10.07
质谱(m/z):311(M++1)
核磁共振谱(CDC3,TMS内标)
δ:1.28(2H,m),1.48(1H,m),1.61-1.83(7H,m),2.08-2.13(1H,m),2.24-2.60(1H,m),2.34(1H,t),2.88(1H,d),3.23(1H,d),3.40-3.45(1H,m),3.79(2H,s),7.22(1H,t),7.36(1H,t),7.47(1H,d),7.78(1H,d)实施例70
往2-〔2-(1-硝基环己基)乙基〕-8H-茚并〔1,2-d〕噻唑910mg在甲醇10ml中的溶液中,依次加入硫酸亚铁·7水合物390mg、还原铁290mg、水30ml、浓硫酸1.5g,加热回流2小时。将反应液注入1N盐酸中,通过乙酸乙酯提取将未反应的原料除去。接着,中和水层,用乙酸乙酯提取。将有机层用水、饱和氯化钠水溶液洗涤,再用无水硫酸镁干燥。减压下蒸去溶剂,得到呈游离碱的黄色的2-〔2-(1-氨基环己基)乙基〕-8H-茚并〔1,2-d〕噻唑120mg。将该碱溶解于乙醇中,加入富马酸进行结晶后,再重结晶,制成富马酸盐。
熔点:162-164℃(乙醇)
元素分析(C18H22N2S·C4H4O4·0.75H2O)
C(%) H(%) N(%) S(%)
理论值 61.73 6.48 6.54 7.49
实验值 62.06 6.83 6.42 7.15
质谱(m/z):299(M++1)
核磁共振谱(DMSO-d6,TMS内标)δ:1.20-1.80(10H,m),2.11(2H,t,J=8.5Hz),3.19(2H,t,J=8.5Hz),3.91(2H,s),6.47(2H,s),7.26(1H,t,J=7.5Hz),7.37(1H,t,J=7.5Hz),7.56(1H,d,J=7.5Hz),7.62(1H,d,J=7.5Hz)实施例71
将2-〔(哌啶子基羰基)甲基〕-8H-茚并〔1,2-d〕噻唑500mg在10ml四氢呋喃中的溶液,于0℃加入氢化铝锂160mg在10ml四氢呋喃中的悬浮液中,加热回流1.5小时。再冷却至0℃温,加入硫酸钠·10水合物,室温下搅拌30分钟,滤去不溶物后,蒸去溶剂,将所得油状物通过硅胶层析柱色谱(洗脱液∶氯仿/甲醇=10∶1)进行纯化,得到2-(2-哌啶子基乙基)-8H-茚并〔1,2-d〕噻唑120mg。将该碱溶解于乙醇中,加入富马酸进行结晶后,再重结晶,制成富马酸盐。
熔点:133-135℃(乙醇)
元素分析(C17H20N2S·C4H4O4·0.5H2O)
C(%) H(%) N(%) S(%)
理论值 61.59 6.15 6.84 7.83
实验值 61.61 6.00 6.76 7.93
质谱(m/z):284(M+)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.35-1.70(6H,m),2.55-2.70(4H,br),2.88(2H,t,J=7.0Hz),3.31(2H,t,J=7.0Hz),3.90(2H,s),6.60(2H,s),7.25(1H,t,J=7.5Hz),7.36(1H,t,J=7.5Hz),7.55(1H,d,J=7.5Hz),7.62(1H,d,J=7.5Hz)实施例72
往2-(1-甲基-2-羰基-4-吡咯烷基)-8H-茚并〔1,2-d〕噻唑0.11g在4ml四氢呋喃中的溶液中,加入甲硼烷-四氢呋喃配合物在四氢呋喃中的1M溶液1.6ml,加热回流2小时。将反应液冷却后,加入浓硫酸10ml和甲醇10ml的混合液,加热回流1.5小时。蒸去溶剂,往残渣中加入乙酸乙酯和水,用1N盐酸提取。用碳酸氢钠将水层中和后,用氯仿提取,再用无水硫酸镁干燥。蒸去溶剂,将所得残渣用硅胶层析柱进行色谱分离,从氯仿-甲醇-29%氨水(300∶10∶1)洗脱部分得到2-(1-甲基-3-吡咯烷基)-8H-茚并〔1,2-d〕噻唑。将该碱溶解于甲醇中,加入富马酸,用丙酮进行结晶,制成富马酸盐。
熔点:129-131℃(丙酮)
元素分析(C15H16N2S·C4H4O4·0.1H2O)
C(%) H(%) N(%) S(%)
理论值 60.98 5.44 7.49 8.57
实验值 60.80 5.35 7.48 8.30
质谱(m/z):256(M+)
核磁共振谱(DMSO-d6,TMS内标)
δ:2.09-2.13(1H,m),2.38-2.47(4H,m),2.74(1H,q),2.84-2.92(2H,m),3.10(1H,t),3.87-3.93(3H,m),6.59(2H,s),7.25(1H,t),7.36(1H,t),7.56(1H,d),7.63(1H,d)实施例73
往2-〔(1-乙氧羰基-4-哌啶基)甲基〕-8H-茚并〔1,2-d〕噻唑0.25g中,加入25%氢溴酸-乙酸溶液10ml,加热回流1小时。将反应液冷却后,加入水,用1N氢氧化钠水溶液和碳酸钾调成碱性后,用氯仿提取。再用无水碳酸钾干燥,蒸去溶剂,得到2-(4-哌啶基甲基)-8H-茚并〔1,2-d〕噻唑0.23g。将该碱溶解于甲醇中,加入富马酸,用乙腈进行结晶后,再用乙腈-甲醇进行重结晶,制成富马酸盐。
熔点:188-189℃(乙腈-甲醇)
元素分析(C16H18N2S·C4H4O4·0.3H2O)
C(%) H(%) N(%) S(%)
理论值 61.30 5.81 7.15 8.18
实验值 61.25 5.69 7.11 8.14
质谱(m/z):270(M+)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.40-1.47(2H,m),1.82(2H,d),2.02-2.05(1H,m),2.81(2H,t),3.04(2H,d),3.21(2H,d),3.91(2H,s),6.43(2H,s),7.25(1H,t),7.36(1H,t),7.56(1H,d),7.63(1H,d)实施例74
往2-〔(3-乙酰氨基-1-吡咯烷基)甲基〕萘并〔1,2-d〕噻唑0.11g在5ml乙醇中的溶液中,加入6N盐酸5ml,加热回流1.5小时。将反应液冷却后,加入乙酸乙酯,用1N盐酸提取。将水层用碳酸氢钠中和后,用氯仿提取,再用无水硫酸镁干燥。蒸去溶剂,得到2-〔(3-氨基-1-吡咯烷基)甲基〕萘并〔1,2-d〕噻唑0.05g。将该碱溶解于甲醇中,加入富马酸,用乙酸乙酯进行结晶后,再用乙腈-甲醇进行重结晶,制成富马酸盐。
熔点:188-189℃(乙腈-甲醇)
元素分析(C16H17N3S·C4H4O4·0.4H2O)
C(%) H(%) N(%) S(%)
理论值 59.46 5.36 10.40 7.94
实验值 59.29 5.33 10.42 8.12
质谱(m/z):282(M+-1)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.72-1.80(1H,m),2.14-2.33(1H,m),269-2.76(2H,m),2.89-3.01(2H,m),3.68-3.73(1H,m),4.23(2H,dd),6.43(2H,s),7.62(1H,t),7.70(1H,t),7.93(1H,d),8.08(1H,d),8.13(1H,d),8.64(1H,d)实施例75
将2-(3-哌啶基甲基)-8H-茚并〔1,2-d〕噻唑94mg溶解于甲酸0.13ml和35%甲醛水溶液0.3ml中,于90℃加热14小时。将反应液用水和氯仿稀释,加入碳酸钾,使水层的pH调成8左右。分出有机层,再用氯仿提取水层2次。合并有机层,用饱和氯化钠水溶液洗涤后,再用无水硫酸钠干燥,减压下蒸去溶剂。将残渣通过硅胶层析柱色谱(洗脱溶剂:氯仿-甲醇)进行纯化,得到褐色油状物99mg。将该油状物溶解于乙腈1ml中,加入富马酸40mg,室温下搅拌30分钟后,滤取生成的结晶,得到2-〔(1-甲基-3-哌啶基)甲基〕-8H-茚并〔1,2-d〕噻唑富马酸盐90mg。
熔点:153℃(分解)(乙腈)
元素分析(C17H20N2S·C4H4O4·0.5H2O)
C(%) H(%) N(%) S(%)
理论值 61.59 6.15 6.84 7.83
实验值 61.40 5.83 6.65 8.06
质谱(m/z):285(M++1)核磁共振谱(DMSO-d6,TMS内标)
δ:1.08-1.20(1H,m),1.58-1.80(3H,m),2.19-2.30(1H,m),2.32-2.53(5H,m),3.03-3.15(m,4H),3.91(s,2H),6.55(2H,s),7.23-7.29(1H,m),7.36(1H,t,J=7.3Hz),7.56(1H.d,J=7.3Hz),7.65(1H,d,J=7.3Hz)
2-〔(1-甲基-3-吡咯烷基)甲基〕-8H-茚并〔1,2-d〕噻唑富马酸盐
原料化合物:2-(3-吡咯烷基甲基)-8H-茚并〔1,2-d〕噻唑
熔点:142-143℃(丙酮/乙腈)
元素分析(C16H18N2S·C4H4O4)
C(%) H(%) N(%) S(%)
理论值 62.16 5.74 7.25 8.30
实验值 62.11 5.69 7.22 8.31
质谱(m/z):271(M++1)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.65-1.74(1H,m),2.06-2.14(1H,m),2.56(3H,s),2.74-2.82(2H,m),2.91-3.03(2H,m),3.09-3.15(1H,m),3.19-3.23(2H,m),3.91(2H,s),6.52(2H,s),7.24(1H,t),7.37(1H,t),7.56(1H,d),7.64(1H,d)实施例77
2-〔(1-甲基-2-吡咯烷基)甲基〕-8H-茚并〔1,2-d〕噻唑富马酸盐
原料化合物:2-(2-吡咯烷基甲基)-8H-茚并〔1,2-d〕噻唑
熔点:172℃(分解)(乙腈)
元素分析(C16H18N2S·C4H4O4·0.2H2O)
C(%) H(%) N(%) S(%)
理论值 61.58 5.79 7.18 8.22
实验值 61.59 5.69 7.25 8.17
质谱(m/z):271(M++1)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.59-1.77(3H,m),1.92-1.99(1H,m),2.44-2.54(4H,m),2.97-3.05(1H,m),3.15-3.24(2H,m),3.48-3.53(1H,m),3.91.(2H,s),6.58(2H,s),7.23-7.27(1H,m),7.34-7.38(1H,m),7.56(1H,d,J=7.3Hz),7.64(1H,d,J=7.3Hz)实施例78
2-〔(1-甲基-4-吡咯烷基)甲基〕-8H-茚并〔1,2-d〕噻唑原料化合物:2-(4-吡咯烷基甲基)-8H-茚并〔1,2-d〕噻唑熔点:81-84℃(乙醚/己烷)
质谱(m/z):284(M+)
核磁共振谱(CDCl3,TMS内标)
δ:1.43(2H,dq),1.78(2H,d),1.84(1H,m),1.94(2H,t),2.26(3H,s),2.85(2H,d),3.02(2H,d),3.80(2H,s),7.23(1H,t),7.37(1H,t),7.49(1H,d),7.77(1H,d)实施例79
2-〔2-(1-二甲基氨基环己基)乙基〕-8H-茚并〔1,2-d〕噻唑富马酸盐原料化合物:2-〔2-(1-氨基环己基)乙基〕-8H-茚并〔1,2-d〕噻唑
熔点:196℃(分解)(乙醇)
元素分析(C20H26N2S·C4H4O4)
C(%) H(%) N(%) S(%)
理论值 65.13 6.83 6.33 7.25
实验值 64.97 6.81 6.17 7.19
质谱(m/z):327(M++1)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.30-1.70(10H,m),1.94(2H,m),2.30(6H,s),3.04(2H,m),3.90(2H,s),6.59(2H,s),7.25(1H,t,J=8.0Hz),7.36(1H,t,J=8.0Hz),7.55(1H,d,J=8.0Hz),7.63(1H,d,J=8.0Hz)实施例80
将2-(1-甲基-3-吡咯烷基)-8H-茚并〔1,2-d〕噻唑30mg溶解于2ml碘甲烷中,室温下搅拌18小时。减压蒸去溶剂,将所得油状物用乙醚-氯仿-甲醇进行结晶,得到碘化1,1-二甲基-3-(8H-茚并〔1,2-d〕噻唑-2-基)吡咯烷鎓
熔点:195-197℃(乙醚-氯仿-甲醇)
质谱(m/z):271(M+)
核磁共振谱(DMSO-d6,TMS内标)
δ:2.50-2.57(1H,m),2.74-2.83(1H,m),3.23(3H,s),3.30(3H,s),3.69-3.81(2H,m),3.89(1H,dd),3.96(2H,s),4.10(1H,dd),4.39-4.48(1H,m),7.27-7.31(1H,t),7.39(1H,t),7.59(1H,d),7.64(1H,d)实施例81
往2-(3-吡咯烷基)-8H-茚并〔1,2-d〕噻唑75mg在1.4ml二氯甲烷中的溶液中,加入乙酸0.18ml、丙酮0.045ml和三乙酰氧基氢化硼钠147mg,室温下搅拌2小时。往反应液中加入水和饱和碳酸氢钠水溶液,用氯仿提取,再用无水硫酸镁干燥。蒸去溶剂,将所得残渣通过硅胶层析柱色谱(洗脱溶剂∶氯仿/甲醇/29%氨水=300∶10∶1)进行纯化,得到2-(1-异丙基-3-吡咯烷基)-8H-茚并〔1,2-d〕噻唑30mg。将该碱溶解于甲醇中,加入富马酸进行结晶,然后再用乙腈-甲醇进行重结晶,制成富马酸盐。
熔点:141-143℃(乙腈-甲醇)
元素分析(C17H20N2S·C4H4O4·0.4H2O)
C(%) H(%) N(%) S(%)
理论值 61.87 6.13 6.87 7.87
实验值 61.79 6.08 6.86 7.90
质谱(m/z):285(M++1)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.10-1.13(6H,m),2.03-2.12(1H,m),2.34-2.43(1H,m),2.67-2.70(1H,m),2.79-2.85(1H,m),2.89-2.97(2H,m),3.16-3.21(1H,m),3.82-3.91(3H,m),6.58(2H,s),7.25(1H,t),7.36(1H,t),7.57(1H,d),7.62(1H,d),13.00(1H,br)实施例82
将2-(叔丁氧羰基氨基)环戊烷硫代甲酰胺0.63g和2-溴-1-茚酮0.54g溶解于50ml异丙醇中,添加碳酸钙0.26g后,加热回流3小时。冷却后,滤去不溶物,蒸去溶剂。将所得残渣进行硅胶层析柱色谱分离,用氯仿-甲醇-29%氨水(100∶10∶1)进行洗脱,并将所得结晶用乙醚进行重结晶,得到2-〔2-(叔丁氧羰基氨基)环戊基〕-8H-茚并〔1,2-d〕噻唑0.11g。
熔点:155-158℃(乙醚)
元素分析(C20H24N2O2S)
C(%) H(%) N(%) S(%)
理论值 67.39 6.79 7.86 8.99
实验值 67.61 6.86 7.81 9.05
质谱(m/z):357(M++1)
核磁共振谱(CDCl3,TMS内标)
δ:1.36(9H,s),1.56-1.65(1H,m),1.81-1.94(2H,m),2.03-2.10(1H,m),2.26-2.36(2H,m),3.36(1H,br),3.80(2H,s),4.08-4.16(1H,m),7.21-7.26(1H,m),7.36(1H,t),7.48(1H,d),7.75(1H,d)
2-〔2-(叔丁氧羰基氨基)环己基〕-8H-茚并〔1,2-d〕噻唑
2-(叔丁氧羰基氨基)环己烷硫代甲酰胺
质谱(m/z):371(M++1)
核磁共振谱(CDCl3,TMS内标)
δ:1.25-2.00(17H,m),3.57(1H,br),4.10(1H,m),7.22-7.24(1H,m),7.38(1H,t),7.49(1H,d),7.76(1H,d)实施例84
将2-〔2-(叔丁氧羰基氨基)环戊基〕-8H-茚并〔1,2-d〕噻唑155mg溶解于6ml乙酸乙酯中,加入4N氯化氢-乙酸乙酯溶液15ml,室温下搅拌1小时。滤取析出的结晶,用乙酸乙酯-甲醇重结晶,得到2-(2-氨基环戊基)-8H-茚并〔1,2-d〕噻唑·2盐酸盐39mg。
熔点:143-146℃(乙酸乙酯-甲醇)
元素分析(C15H16N2S·2HCl·0.3H2O)
C(%) H(%) N(%) S(%) Cl(%)
理论值 53.83 5.60 8.37 9.58 21.18
实验值 54.19 5.53 8.48 9.41 20.87
质谱(m/z):257(M++1)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.78-1.99(3H,m),2.09-2.24(3H,m),3.81-3.88(2H,m),3.94(2H,s),7.26-7.30(1H,m),7.39(1H,t),7.59(1H,d),7.70(1H,s)
2-(2-氨基环己基)-8H-茚并〔1,2-d〕噻唑·2盐酸盐
原料化合物:2-〔2-(叔丁氧羰基氨基)环己基-8H-茚并〔1,2-d〕噻唑
熔点:256℃(分解)(乙酸乙酯/甲醇)
质谱(m/z):271(M++1)
核磁共振谱(DMSO-d6,TMS内标)
δ:1.52-2.10(8H,m),3.68-3.71(2H,m),3.95(2H,s),7.28(1H,t),7.39(1H,t),7.59(1H,d),7.74(1H,d)
除上面列举的化合物外,下述化合物(表5,实施例B-1~100)可根据上述制造方法、实施例中记载的方法及其改良法或本领域技术人员公知的制造方法及其改良法进行合成而不需要特别的实验。
Claims (17)
1)苯环,或
2)含有一个或多个选自氮原子、氧原子或硫原子的杂原子的5员或6员不饱和杂环;L1和L2:其中的一个为单键,另一个不存在或表示具有1-4个碳原子的亚烷基或具有2-5个碳原子的亚链烯基;R:下式表示的基团:L3:低级亚烷基;L4:单键或低级亚烷基;R1和R2:相同或不同,表示氢原子、低级烷基或氨基保护基;R3:氢原子、低级烷基、桥氧基或可被保护的氨基;R4:不存在或表示氢原子、低级烷基、芳烷基或氨基保护基;B环:可分别含有氧原子的下述单环或二环:
1)具有4-16个成环原子的含氮杂环,或
2)含1个不饱和键的具有4-16个成环原子的含氮杂环;D环:具有4-8个成环原子的饱和碳环;
但R中的氮原子可成为伴有取代基的季胺盐。
2.如权利要求1所述的5-HT3受体激动剂,其特征在于,它是一种消化道运动障碍的预防和/或治疗剂。
3.通式(II)表示的噻唑衍生物或其药学上可接受的盐:式中符号的定义如下:A环:可被一个或多个选自卤原子、低级烷基和低级烷氧基的取代基分别取代的下述环:
1)苯环,或
2)含有一个或多个选自氮原子、氧原子或硫原子的杂原子的5员或6员不饱和杂环;L1和L2:其中的一个为单键,另一个不存在或表示具有1-4个碳原子的亚烷基或具有2-5个碳原子的亚链烯基;R:下式表示的基团:L3:低级亚烷基;L4:单键或低级亚烷基;R1和R2:相同或不同,表示氢原子、低级烷基或氨基保护基;R3:氢原子、低级烷基、桥氧基或可被保护的氨基;R4:不存在或表示氢原子、低级烷基、芳烷基或氨基保护基;B环:可含有氧原子的下述单环或二环:
1)具有4-16个成环原子的含氮杂环,或
2)含1个不饱和键的具有4-16个成环原子的含氮杂环;D环:具有4-8个成环原子的饱和碳环;
但当A环为苯环或吡啶环时,L1和L2中的一个表示单键,另一个表示具有1-4个碳原子的亚烷基或具有2-5个碳原子的亚链烯基;另外,R中的氮原子可成为伴有取代基的季胺盐。
7.如权利要求3所述的化合物,其特征在于,该化合物由通式(IId)表示式中,A环、L1a、L2a、L4、D环、R1和R2的定义同上。
8.如权利要求3所述的化合物,其特征在于,该化合物由通式(IIe)表示式中,L4、B环、R3和R4的定义同上,A1环表示可被一个或多个选自卤原子、低级烷基和低级烷氧基的取代基取代的、含一个或多个选自氮原子、氧原子、硫原子的杂原子的5员或6员不饱和杂环,但吡啶环除外。
12.如权利要求7所述的化合物,其特征在于,该化合物由通式(IIId)表示式中A2环、L2b、n和D环的定义同上,R1a和R2b相同或不同,表示氢原子或低级烷基。
14.如权利要求11所述的化合物,其特征在于,该化合物中的B环为1-氮杂二环〔3.3.0〕辛烷环或1-氮杂二环〔2.2.1〕庚烷环。
15.如权利要求11所述的化合物,其特征在于,该化合物中的B环为吡咯烷环。
16. 2-(3-吡咯烷基)-8H-茚并〔1,2-d〕噻唑
(3R*,5S*)-3-(8H-茚并〔1,2-d〕噻唑-2-基)-1-氮杂二环〔3.3.0〕辛烷
2-(3-吡咯烷基甲基)-8H-茚并〔1,2-d〕噻唑
4-(8H-茚并〔1,2-d〕噻唑-2-基)-1-氮杂二环〔2.2.1〕庚烷
(S)-2-(3-吡咯烷基)-8H-茚并〔1,2-d〕噻唑
(3R,5S)-3-(8H-茚并〔1,2-d〕噻唑-2-基)-1-氮杂二环〔3.3.0〕辛烷
(3S,5R)-3-(8H-茚并〔1,2-d〕噻唑-2-基)-1-氮杂二环〔3.3.0〕辛烷
2-(1-甲基-3-吡咯烷基)-8H-茚并〔1,2-d〕噻唑
5-〔(8H-茚并〔1,2-d〕噻唑-2-基)-1-氮杂二环〔3.3.0〕辛烷或它们的药学上可接受的盐。
17.选自(1-苄基-3-吡咯烷)硫代甲酰胺、(1-苄基-吡咯烷基)硫代乙酰胺、1-氮杂二环[2.2.1〕庚烷-4-硫代甲酰胺、1-甲基-2-吡咯烷基-4-硫代甲酰胺和1-氮杂二环[3.3.0〕辛烷-3-硫代甲酰胺之类的硫代甲酰胺衍生物或它们的盐。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP67822/94 | 1994-03-11 | ||
JP6782294 | 1994-03-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1143364A true CN1143364A (zh) | 1997-02-19 |
Family
ID=13356027
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN95192012A Pending CN1143364A (zh) | 1994-03-11 | 1995-03-09 | 5-ht3受体激动剂、新颖的噻唑衍生物及其中间体 |
Country Status (9)
Country | Link |
---|---|
US (1) | US5834499A (zh) |
EP (1) | EP0749966A4 (zh) |
KR (1) | KR970701705A (zh) |
CN (1) | CN1143364A (zh) |
AU (1) | AU686340B2 (zh) |
CA (1) | CA2184685A1 (zh) |
MX (1) | MX9603998A (zh) |
NZ (1) | NZ281718A (zh) |
WO (1) | WO1995024399A1 (zh) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19844547C2 (de) * | 1998-09-29 | 2002-11-07 | Aventis Pharma Gmbh | Polycyclische Dihydrothiazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE19908535A1 (de) * | 1999-02-26 | 2000-08-31 | Aventis Pharma Gmbh | Verwendung von polycyclischen Thiazol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas |
DE19908533A1 (de) * | 1999-02-26 | 2000-08-31 | Aventis Pharma Gmbh | Polycyclische Thiazol-Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen |
DE19908539A1 (de) * | 1999-02-26 | 2000-08-31 | Aventis Pharma Gmbh | Polycyclische 2-Amino-Dihydrothiazolsysteme, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE60025261T2 (de) * | 1999-11-23 | 2006-08-24 | Janssen Pharmaceutica N.V. | Verwendung von 5ht3 antagonisten zur fundusentspannung |
DE10008274A1 (de) | 2000-02-23 | 2001-08-30 | Aventis Pharma Gmbh | Substituierte 8,8a-Dihydro-3aH-indeno[1,2-d]thiazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
JP2004506686A (ja) * | 2000-08-21 | 2004-03-04 | ジョージタウン ユニバーシティ | モノアミン輸送体のモジュレーターとしての2,3−二置換キヌクリジン、及びこれに基づく治療及び診断法 |
GB0321091D0 (en) * | 2003-09-09 | 2003-10-08 | Alizyme Therapeutics Ltd | Synthesis |
EP2332904A3 (en) * | 2004-01-15 | 2012-04-11 | Paratek Pharmaceuticals, Inc. | Derivatives of tetracycline compounds |
US7388027B2 (en) | 2004-03-04 | 2008-06-17 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
US8367696B2 (en) | 2007-02-09 | 2013-02-05 | Astellas Pharma Inc. | Aza-bridged-ring compound |
JP5605844B2 (ja) * | 2008-10-17 | 2014-10-15 | 塩野義製薬株式会社 | 血管内皮リパーゼ阻害活性を有する酢酸アミド誘導体 |
DE102010000662A1 (de) | 2009-03-18 | 2010-10-21 | Bayer Cropscience Ag | Aminopropylthiazol-Derivate als Fungizide |
ES2753582T3 (es) * | 2014-06-11 | 2020-04-13 | Bayer Cropscience Ag | Preparación de piperidin-4-carbotioamida |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1575904A (en) * | 1976-04-23 | 1980-10-01 | Lilly Industries Ltd | Phenyl piperazines |
CA1292226C (en) * | 1986-01-16 | 1991-11-19 | Terumi Hachiya | Indenothiazole derivative and process for preparing the same |
DE3877470T2 (de) * | 1987-09-10 | 1993-06-24 | Merck Sharp & Dohme | Oxazole und thiazole zur behandlung seniler demenz. |
NZ227841A (en) * | 1988-02-12 | 1991-08-27 | Merck Sharp & Dohme | Heterocyclic compounds with at least two non-condensed five membered rings and pharmaceutical compositions |
US4963689A (en) * | 1989-05-19 | 1990-10-16 | Pfizer Inc. | Heterocyclicguanidines as 5HT3 antagonists |
US5424431A (en) * | 1990-10-24 | 1995-06-13 | Yamanouchi Pharmaceutical Co., Ltd. | Thiazole derivatives |
JP2829451B2 (ja) * | 1990-11-30 | 1998-11-25 | 大塚製薬株式会社 | 活性酸素抑制剤 |
US5492919A (en) * | 1991-08-03 | 1996-02-20 | Smithkline Beecham P.L.C. | 5-HT4 receptor antagonists |
JP3197602B2 (ja) * | 1992-02-17 | 2001-08-13 | 久光製薬株式会社 | チアゾール類縁化合物及び皮膚外用剤 |
GB9204958D0 (en) * | 1992-03-06 | 1992-04-22 | Fujisawa Pharmaceutical Co | Thiazole derivatives |
WO1994006791A1 (en) * | 1992-09-14 | 1994-03-31 | Yamanouchi Pharmaceutical Co., Ltd. | Novel condensed thiazole derivative, process for producing the same, and pharmaceutical composition containing the same |
JPH0770136A (ja) * | 1993-08-31 | 1995-03-14 | Yamanouchi Pharmaceut Co Ltd | 新規縮合チアゾール誘導体 |
WO1995024406A1 (fr) * | 1994-03-10 | 1995-09-14 | Yamanouchi Pharmaceutical Co., Ltd. | NOUVEAU DERIVE de 2-(IMIDAZOLYLMETHYL)THIAZOLE ET COMPOSITION MEDICALE ISSUE DE CE DERIVE |
-
1995
- 1995-03-09 EP EP95910774A patent/EP0749966A4/en not_active Withdrawn
- 1995-03-09 KR KR1019960705029A patent/KR970701705A/ko not_active Application Discontinuation
- 1995-03-09 CN CN95192012A patent/CN1143364A/zh active Pending
- 1995-03-09 AU AU18622/95A patent/AU686340B2/en not_active Ceased
- 1995-03-09 MX MX9603998A patent/MX9603998A/es unknown
- 1995-03-09 US US08/700,428 patent/US5834499A/en not_active Expired - Fee Related
- 1995-03-09 NZ NZ281718A patent/NZ281718A/xx unknown
- 1995-03-09 WO PCT/JP1995/000385 patent/WO1995024399A1/ja not_active Application Discontinuation
- 1995-03-09 CA CA002184685A patent/CA2184685A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US5834499A (en) | 1998-11-10 |
WO1995024399A1 (fr) | 1995-09-14 |
AU686340B2 (en) | 1998-02-05 |
AU1862295A (en) | 1995-09-25 |
EP0749966A4 (en) | 1997-07-02 |
MX9603998A (es) | 1997-12-31 |
NZ281718A (en) | 1997-08-22 |
KR970701705A (ko) | 1997-04-12 |
EP0749966A1 (en) | 1996-12-27 |
CA2184685A1 (en) | 1995-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1024547C (zh) | 一类环胺化合物的制备方法 | |
CN1048484C (zh) | 含苯并杂环化合物的药物组合物的制备方法 | |
CN1035944C (zh) | 3-氨基哌啶衍生物及有关的含氮杂环化合物的制备方法 | |
CN1088917A (zh) | 取代的苄氨基含氮非芳族杂环化合物 | |
CN1046721C (zh) | 杂环化合物及其制备方法和用途 | |
CN1044117C (zh) | 用于抑制人免疫缺陷病毒蛋白酶的化合物及其制备方法和药物用途 | |
CN1064682C (zh) | 具有磷脂酶a2抑制活性的吡咯烷衍生物 | |
CN1118457C (zh) | 新的环状二胺化合物及含有它的药物 | |
CN1443167A (zh) | 用于治疗5-羟色胺相关性疾病的氮杂环化合物 | |
CN101048393A (zh) | 作为γ-分泌酶抑制剂的取代的N-芳基磺酰基杂环胺 | |
CN1030415A (zh) | 饱和的杂环碳酰胺衍生物和它的制备方法 | |
CN1745063A (zh) | 阻碍二肽基肽酶ⅳ的化合物 | |
CN1444573A (zh) | 甲酰胺化合物及其作为人11cby受体拮抗剂的用途 | |
CN1143364A (zh) | 5-ht3受体激动剂、新颖的噻唑衍生物及其中间体 | |
CN1432015A (zh) | 可用作细胞增殖抑制剂的被1,1-二氧代异噻唑烷取代的吲唑 | |
CN1030252C (zh) | 四氢苯并咪唑衍生物的制备方法 | |
CN1014790B (zh) | 新型苯并唑基及苯并噻唑基胺类衍生物的制备方法及其应用 | |
CN1657523A (zh) | 环状化合物 | |
CN1044656A (zh) | 吡唑并吡啶化合物及其制备方法 | |
CN1905868A (zh) | Dpp-iv抑制剂 | |
CN1374959A (zh) | 喹啉基丙基哌啶衍生物及其作为抗菌剂的用途 | |
CN1993363A (zh) | 1,3-二取代的杂芳基nmda/nr2b拮抗剂 | |
CN1491225A (zh) | 三杂环化合物和包括其作为活性组分的药物 | |
CN1471536A (zh) | 趋化因子受体拮抗剂及其使用方法 | |
CN1505630A (zh) | 吡唑并[1,5-a]吡啶化合物及其药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C01 | Deemed withdrawal of patent application (patent law 1993) | ||
WD01 | Invention patent application deemed withdrawn after publication |